Refine
Has Fulltext
- yes (467) (remove)
Is part of the Bibliography
- yes (467)
Year of publication
Document Type
- Journal article (237)
- Doctoral Thesis (229)
- Conference Proceeding (1)
Keywords
- Schizophrenie (39)
- schizophrenia (30)
- ADHD (28)
- depression (26)
- Depression (23)
- Serotonin (20)
- fNIRS (14)
- Medizin (12)
- anxiety (12)
- bipolar disorder (12)
- ADHS (11)
- Angststörung (11)
- Aufmerksamkeits-Defizit-Syndrom (11)
- EEG (11)
- Polymorphismus (11)
- fMRI (11)
- hippocampus (10)
- prefrontal cortex (10)
- serotonin (10)
- Angst (9)
- NIR-Spektroskopie (9)
- NIRS (9)
- Präfrontaler Cortex (9)
- genetics (9)
- working memory (9)
- DNA methylation (8)
- Schizophrenia (8)
- panic disorder (8)
- Arbeitsgedächtnis (7)
- BDNF (7)
- Hippocampus (7)
- Neurogenese (7)
- Panikstörung (7)
- ERN (6)
- Genexpression (6)
- Impulsivität (6)
- Kandidatengen (6)
- Leonhard classification (6)
- Leonhard-Klassifikation (6)
- P300 (6)
- Psychiatrie (6)
- Stickstoffmonoxid (6)
- Stickstoffmonoxid-Synthase (6)
- Stress (6)
- Vagus (6)
- epigenetics (6)
- fear conditioning (6)
- gene expression (6)
- mice (6)
- polymorphism (6)
- tDCS (6)
- Alzheimer-Krankheit (5)
- Aufmerksamkeit (5)
- COMT (5)
- Dopamin (5)
- EKP (5)
- Elektroencephalogramm (5)
- Ereigniskorreliertes Potenzial (5)
- Furcht (5)
- Karl Leonhard (5)
- Knockout (5)
- Maus (5)
- Quantitative anatomy (5)
- amygdala (5)
- antidepressant (5)
- antidepressants (5)
- anxiety disorders (5)
- brain (5)
- dementia (5)
- dentate gyrus (5)
- dopamine (5)
- gene (5)
- near-infrared spectroscopy (5)
- oxidative stress (5)
- psychiatry (5)
- 5-HTTLPR (4)
- Alkoholabhängigkeit (4)
- Alzheimer disease (4)
- Alzheimerkrankheit (4)
- Alzheimer’s disease (4)
- Arzneimittelüberwachung (4)
- Assoziationsstudie (4)
- Bipolar disorder (4)
- Brain-derived neurotrophic factor (4)
- COVID-19 (4)
- Catecholmethyltransferase <Catechol-0-Methyltransferase> (4)
- ERP (4)
- Emotionsregulation (4)
- Epigenetik (4)
- Funktionelle Kernspintomografie (4)
- Herzfrequenzvariabilität (4)
- Knockout <Molekulargenetik> (4)
- Konditionierung (4)
- Manisch-depressive Krankheit (4)
- Molekulargenetik (4)
- NPY (4)
- Pe (4)
- SNP (4)
- Startle (4)
- adult neurogenesis (4)
- behavior (4)
- candidate gene (4)
- extinction (4)
- genome-wide association (4)
- knockout (4)
- major depression (4)
- mental disorders (4)
- mouse model (4)
- neuroprotection (4)
- periodic catatonia (4)
- pregnancy (4)
- serotonin transporter (4)
- 5-HT1A (3)
- 5-HT2C (3)
- Albino rats (3)
- Alkoholismus (3)
- Alzheimer (3)
- Alzheimer's disease (3)
- Alzheimers disease (3)
- Amygdala (3)
- Angsterkrankungen (3)
- Angstsensitivität (3)
- Antidepressiva (3)
- Anxiety (3)
- Association study (3)
- Biomarker (3)
- Bipolare Störung (3)
- Cerebellar cortex (3)
- DAT (3)
- Demenz (3)
- Elektroencephalographie (3)
- Emotion (3)
- Ereigniskorrelierte Potentiale (3)
- Extinktion (3)
- FKBP5 (3)
- Genanalyse (3)
- Genetik (3)
- Haplotypanalyse (3)
- ICD-10 (3)
- MDD (3)
- MRI (3)
- Methylphenidat (3)
- Morbus Alzheimer (3)
- NGA (3)
- Paniksyndrom (3)
- Persönlichkeit (3)
- Persönlichkeitsstörung (3)
- Pharmakokinetik (3)
- Präfrontaler Kortex (3)
- Purkinje cells (3)
- Serotoninstoffwechsel (3)
- Stathmin (3)
- adulte Neurogenese (3)
- age (3)
- aggression (3)
- association (3)
- attentional bias (3)
- children (3)
- cycloid psychosis (3)
- emotion (3)
- emotional regulation (3)
- executive functions (3)
- fear (3)
- glucocorticoid receptor (3)
- glucose transporter (3)
- humans (3)
- impulsivity (3)
- life events (3)
- major depressive disorder (3)
- mental health (3)
- mild cognitive impairment (3)
- neurodegeneration (3)
- neuroimaging (3)
- neuroinflammation (3)
- neuromelanin (3)
- neuropathology (3)
- polygenic risk score (3)
- psychiatric disorders (3)
- response inhibition (3)
- spider phobia (3)
- stress (3)
- substantia nigra (3)
- therapeutic drug monitoring (3)
- transcranial direct current stimulation (3)
- Ängstliche Depression (3)
- 5-HT transporter (2)
- 5-HT1A receptor (2)
- 5-HTT (2)
- Adult (2)
- Agoraphobie (2)
- Altersdepression (2)
- Antiepileptika (2)
- Antipsychotika (2)
- Antworthemmung (2)
- Approach-Avoidance-Task (2)
- Aufmerksamkeitsdefizit-Syndrom (2)
- Aufmerksamkeitskontrolle (2)
- Aufmerksamkeitslenkung (2)
- Aufmerksamkeitsverzerrung (2)
- Big Five (2)
- CA3 (2)
- CNV (2)
- CPT (2)
- CSF (2)
- Cadherine (2)
- Cerebellum (2)
- Cluster C Persönlichkeitsstörungen (2)
- Coexpression (2)
- Coffin-Lowry syndrome (2)
- Corpus striatum (2)
- Cue-Reaktivität (2)
- Cytokines (2)
- DNA (2)
- DNA methyltransferases (2)
- DNMT3A (2)
- Duplikation (2)
- EDA (2)
- Elektrophysiologie (2)
- Emotional processing (2)
- Erwachsener (2)
- Escitalopram (2)
- Expositionstherapie (2)
- FAAH (2)
- FMRI (2)
- Fehlerverarbeitung (2)
- Fibromyalgia syndrome (2)
- Frühdiagnostik (2)
- Furchtkonditionierung (2)
- GABA (2)
- GLUT3 (2)
- Gehirn (2)
- Gen (2)
- Genmutation (2)
- HPA axis (2)
- Haplotyp (2)
- Hautleitfähigkeit (2)
- IAPS (2)
- Inflammation (2)
- Inhibition (2)
- Insulin (2)
- Katatonie (2)
- Ki-67 (2)
- Klassifikation der endogenen Psychosen (2)
- Kognition (2)
- Konflikterkennung (2)
- LORETA (2)
- Lebensqualität (2)
- Leichte kognitive Beeinträchtigung (2)
- Lipofuscin (2)
- MEG (2)
- MLC1 (2)
- Mice (2)
- Migräne (2)
- Monoaminoxidase (2)
- NOS1AP (2)
- NPSR1 (2)
- Nah-Infrarot-Spektroskopie (2)
- Neuroendokrines System (2)
- Neurotransmitter (2)
- OCD (2)
- P50 (2)
- PARK2 (2)
- PFC (2)
- Parkinson disease (2)
- Parkinson's disease (2)
- Parkinson-Krankheit (2)
- Parkinson’s disease (2)
- Persönlichkeitsmerkmale (2)
- Pharmakotherapie (2)
- Phobie (2)
- Polymerase-Kettenreaktion (2)
- Prefrontal cortex (2)
- Promotor (2)
- Promotorpolymorphismus (2)
- Prävention (2)
- Psychiatric disorders (2)
- Psychopathologie (2)
- Psychopharmaka (2)
- Psychopharmakon (2)
- Q-T-Verlängerung (2)
- Qualitätssicherung (2)
- RSK2 (2)
- Rauchen (2)
- Rehabilitation (2)
- SERT (2)
- SLC12A6 (2)
- SLC2A3 (2)
- Schreckreaktion (2)
- Schwangerschaft (2)
- Senile Demenz (2)
- Serotonin transporter (2)
- Serotonin-Transporter (2)
- Serotonintransporter (2)
- Serumkonzentration (2)
- Somatosensorisch evoziertes Potenzial (2)
- Stereology (2)
- Stickstoffoxidsynthase (2)
- Stressreaktion (2)
- Thalamus (2)
- Therapeutisches Drug Monitoring (2)
- Tiermodell (2)
- Tryptophan hydroxylase 2 (2)
- VFT (2)
- Vasopressin (2)
- Venlafaxin (2)
- Working memory (2)
- action monitoring (2)
- activation (2)
- active zone (2)
- adult ADHD (2)
- adversity (2)
- affective disorders (2)
- affektive Störungen (2)
- aging (2)
- alliance (2)
- alpha-synuclein (2)
- animal behavior (2)
- anterior cingulate cortex (2)
- anterior insula (2)
- association study (2)
- astrocytes (2)
- attentional control (2)
- behaviour (2)
- biomarker (2)
- biomarkers (2)
- bipolar affective disorder (2)
- cerebellum (2)
- chronic heart failure (2)
- classification of endogenous psychosis (2)
- cognitive control (2)
- cognitive decline (2)
- cognitive impairment (2)
- coping (2)
- cortical activation (2)
- cue-reactivity (2)
- cycloid psychoses (2)
- depressive disorder (2)
- disease progression (2)
- disorder (2)
- dorsolateral prefrontal cortex (2)
- early recognition (2)
- early-life stress (2)
- efficacy (2)
- electroencephalography (2)
- emotion regulation (2)
- endocannabinoid (2)
- endophenotype (2)
- error-related negativity (2)
- event-related potentials (2)
- evoked potentials (2)
- evozierte Potentiale (2)
- expression (2)
- fear generalization (2)
- fear-potentiated startle (2)
- fibromyalgia (2)
- frontotemporal dementia (2)
- functional magnetic resonance imaging (2)
- functional near-infrared spectroscopy (2)
- functional neuroimaging (2)
- glutamate (2)
- hiPSC (2)
- illness (2)
- immediate early genes (2)
- inflammation (2)
- insulin receptor (2)
- iron (2)
- knockout mice (2)
- lactation (2)
- learning (2)
- lithium (2)
- long-term potentiation (2)
- longitudinal studies (2)
- migraine (2)
- monoamine oxidase (2)
- mouse (2)
- mutation (2)
- myelination (2)
- myocardial infarction (2)
- negative affect (2)
- neurodevelopment (2)
- neurogenesis (2)
- neuropsychiatric disorders (2)
- neuropsychology (2)
- nitric oxide synthase (2)
- obesity (2)
- oligodendrocyte (2)
- pain (2)
- parietal hypoactivation (2)
- peripartum (2)
- personality (2)
- personality disorder (2)
- pharmacovigilance (2)
- plasticity (2)
- polymorphisms (2)
- potassium chloride co-transporter 3 (2)
- prediction (2)
- prefrontal activity (2)
- prenatal stress (2)
- promoter polymorphism (2)
- proteomics (2)
- präfrontaler Kortex (2)
- psychopathology (2)
- psychosocial stress (2)
- quality of life (2)
- rat (2)
- reaction time (2)
- regulatory T cells (2)
- reliability (2)
- sensitivity (2)
- serotonin deficiency (2)
- serotonin transporter gene (2)
- serum concentration (2)
- smoking (2)
- social decision-making (2)
- social interaction (2)
- startle reflex (2)
- streptozotocin (2)
- substantia nigra pars compacta (2)
- suicide prevention (2)
- sustained fear (2)
- systematic review (2)
- target (2)
- temporoparietal junction (2)
- transkranielle Gleichstromstimulation (2)
- triple in situ hybridization (2)
- tryptophan (2)
- zykloide Psychose (2)
- "Familiär-sporadisch"- Konzept (1)
- 123I-mIBG (1)
- 1p13.3 (1)
- 1q21 (1)
- 3D reconstruction (1)
- 3D-Rekonstruktion (1)
- 5-HT (1)
- 5-HT1A-Polymorphismus (1)
- 5-HT1A-polymorphism (1)
- 5-HT2A (1)
- 5-HT3A (1)
- 5-HTT knockout mice (1)
- 5-HTT polymorphism (1)
- 5-HTT-Polymorphismus (1)
- 5HT1A (1)
- 5HTT (1)
- 5HTTLPR (1)
- 7q11.2 (1)
- AAT (1)
- ACC (1)
- ACE-Hemmer (1)
- ACE-inhibitor (1)
- ADORA2A (1)
- ASIC1 (1)
- AT1-Rezeptor-Antagonist (1)
- Abelson helper integration-1 (AHI1) (1)
- Abstinenz (1)
- Activation (1)
- Acute tryptophan depletion (1)
- Adaptation (1)
- Adenosin (1)
- Adipositas (1)
- Adult head (1)
- Adulte Neurogenese (1)
- Adults (1)
- Affective psychoses (1)
- Ageing (1)
- Aggression (1)
- Aggressive behaviour (1)
- Akustischer Startle Reflex (1)
- Albino rat (1)
- Albinoratten (1)
- Algorithmus (1)
- Alkohol-Craving tDCS (1)
- Alkoholabhängikeit (1)
- Alkoholkonsum (1)
- Alkoholmissbrauch (1)
- Altersmedizin (1)
- Alterspsychiatrie (1)
- Alzheimer's Dementia (1)
- Alzheimer´s disease (1)
- Alzheimer’s dementia (1)
- Ammonshorn (1)
- Angst als Zustand (1)
- Angsterkrankung (1)
- Angstreaktionen (1)
- Angstsensitivitätsindex-3 (1)
- Angstsyndrom (1)
- Angstverarbeitung (1)
- Animal behavior IntelliCage system (1)
- Animal model (1)
- Animales Nervensystem (1)
- Ankyrin (1)
- Anorexia nervosa (1)
- Anteriorer cingulärer Cortex (1)
- Anteriores Cingulum (1)
- Anti-Suizid-Vertrag (1)
- Antidepressants (1)
- Antidepressivum (1)
- Antikonvulsiva (1)
- Antipsychotics (1)
- Antizipation (1)
- Anxiety Disorders (1)
- Anxiety Sensetivity Index (1)
- Anxiety disorder (1)
- Anxiety disorders (1)
- Anxiety sensitivity (1)
- Anxiety-like behavior (1)
- ApoE-Genotyp (1)
- Apolipoprotein (1)
- Apolipoprotein E (1)
- Arbeitsg (1)
- Arzneimittelinteraktion (1)
- Association analyses (1)
- Associative learning (1)
- Assoziation (1)
- Assoziationsanalyse (1)
- Assoziationsstudien (1)
- Assoziationsuntersuchung (1)
- Assoziatives Lernen (1)
- Astrozyten (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention Switching (1)
- Attention-deficit/hyperactivity disorder (1)
- Atypische Antipsychotika (1)
- Auditory pathway (1)
- Auditory targets (1)
- Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (1)
- Aurikuläre Vagusnervstimulation (1)
- Autismus (1)
- Automatische Annäherungstendenzen (1)
- Automatische Klassifikation (1)
- Autoradiographie (1)
- Autoradiography (1)
- Axonal degeneration (1)
- B 37 CAG repeat locus (1)
- BDNF Astrozyten depressive Episode (1)
- BDNF Val66Met (1)
- BIS (1)
- Balints-Syndrome (1)
- Ballerspiel (1)
- Basalganglien (1)
- Bed nucleus of stria terminalis (1)
- Beer-lambert law (1)
- Befindlichkeit (1)
- Belegung (1)
- Beruf (1)
- Berufsklassifikation (1)
- Bestärkendes Lernen <Künstliche Intelligenz> (1)
- Bias (1)
- Bildgebendes Verfahren (1)
- Biomarke (1)
- Biomarkers (1)
- Bipolar DGKH-GAT Endophänotypen (1)
- Bipolar-affektive Störung (1)
- Bipolare affektive Störung (1)
- Blood-brain barrier (1)
- Blutgerinnung (1)
- Body weight (1)
- Borderline-Persönlichkeitsstörung (1)
- Brain (1)
- Brain atrophy (1)
- Brain mappins (1)
- Brain trauma (1)
- Bromdesoxyuridin <5-Brom-2-desoxyuridin> (1)
- Bulimia nervosa (1)
- C(-1019)G polymorphism (1)
- C-reactive protein (1)
- C-reaktives Protein (1)
- CA4 (1)
- CAPS (1)
- CDH13 (1)
- CDH13 Expression (1)
- CDH13 mRNA (1)
- CERK1 (1)
- CLN3 (1)
- CNS (1)
- CNVs (1)
- COGITAT-Box (1)
- COMT VAL(158)MET polymorphism (1)
- COMT Val 158Met Polymorphism (1)
- COMT-Polymorphismus (1)
- COMT-Val158Met (1)
- CREB (1)
- CRH1 (1)
- CRHR (1)
- CRISPR-Cas Systems (1)
- CRP (1)
- Cadherin (CDH13) (1)
- Cadherin-13 (CDH13) (1)
- Capillaries (1)
- Carbamazepin (1)
- Case-Control Studies (1)
- Catechol-0-Methyltransferase (1)
- Catecholmethyltransferase (1)
- Caudate nucleus (1)
- Cdh13 (1)
- Cerebellar nuclei (1)
- Cerebrolysin (1)
- Cerebrospinal fluid (1)
- Charakterisierung (1)
- Chemische Synthese (1)
- Cholinerges System (1)
- Chromosom 22q11 (1)
- Chronic disease (1)
- Chronic heart failure (1)
- Chronic stress (1)
- Chronische Depression (1)
- Chronische Schizophrenie (1)
- Citalopram (1)
- Claustrum (1)
- Clinical Genetics (1)
- Cluster C personality disorder (1)
- Cluster C personality disorders (1)
- Cognitive Therapy (1)
- Cognitive control (1)
- Cognitive decline (1)
- Comorbidity (1)
- Corpus amygdaloideum (1)
- Covid-19 (1)
- Craving (1)
- Cues (1)
- D-Aminosäure-Oxidase (1)
- D-amino acid oxidase activator (1)
- D-amino-acid-oxidase (1)
- DAOA (1)
- DLPFC (1)
- DNA Methylation (1)
- DNA damage (1)
- DNA-Methylierung (1)
- DNA-Methyltransferasen (1)
- DNMT3B (1)
- DRD2 (1)
- DRD2-Rezeptor-Gen (1)
- DRD4 (1)
- DSM-IV (1)
- DSM-IV-TR (1)
- DYNLL1 (1)
- De-novo (1)
- Delay Aversion (1)
- Delay Discounting (1)
- Deletion <Genetik> (1)
- Dementia (1)
- Demenz vom Alzheimer Typ (1)
- Demyelination (1)
- Demyelinisierung (1)
- Dental Phobia (1)
- Dentalphobie (1)
- Diabetes Mellitus Typ 2 (1)
- Diabetes mellitus (1)
- Diabetic polyneuropathy (1)
- Diagnostic (1)
- Differentielle Genexpression (1)
- Dimension 3 (1)
- Disease progression (1)
- Disease-modifying therapies (1)
- Diskriminanzanalyse (1)
- Disorders (1)
- Dissoziale Persönlichkeitsstörung (1)
- Distress (1)
- Diuretikum (1)
- Dopamin-beta-Hydroxylase (1)
- Dopamine (1)
- Dopamine Transporter (1)
- Dopamine melanin (1)
- Dopaminrezeptor (1)
- Dopaminstoffwechsel (1)
- Dopamintransporter (1)
- Dorsolateral prefrontal cortex (1)
- Dreidimensionale Rekonstruktion (1)
- Drosophila (1)
- Drosophila model (1)
- Drug development (1)
- Duloxetin (1)
- Dynamic Causal Modeling (1)
- Dysbindin (1)
- E3 ubiquitin ligase (1)
- EBM (1)
- EMG (1)
- EPN (1)
- ERN/Ne (1)
- Early Posterior Negativity (1)
- Early infant catatonia (1)
- Early-onset (1)
- Ecological Momentary Assessment (1)
- Ego-Shooter (1)
- Ehescheidung (1)
- Einfühlung <Motiv> (1)
- Einsamkeit (1)
- Elektrotherapie (1)
- Elevated Plus Maze (1)
- Emotionen (1)
- Emotionsverarbeitung (1)
- Endophänotyp (1)
- Enrichment analysis (1)
- Entgiftung (1)
- Entlassungsmanagement (1)
- Entscheidungsprozess (1)
- Entwicklung (1)
- Entzug (1)
- Entzündung (1)
- Entzündungsparameter (1)
- Entzündungsparametern (1)
- Enzym (1)
- EphA4 (1)
- Epigenesis (1)
- Epigenetic (1)
- Ereigniskorrelierte Potentiale EKP (1)
- Eriksen Flanker Task (1)
- Eriksen flanker task (1)
- Eriksen-Flanker-Test (1)
- Erwachsene (1)
- Erwachsenenalter (1)
- Essstörungen (1)
- Europe (1)
- Event related potentials (1)
- Event-related potentials (1)
- Evoked potential (1)
- Evoziertes Potenzial (1)
- Excitatory/inhibitory imbalance (1)
- Exposition (1)
- Expositionsbehandlung (1)
- Expositionslernen (1)
- Exposure treatment (1)
- Expression (1)
- Extraversion (1)
- FEV gene (1)
- FNIRS (1)
- FPI-R (1)
- Familial/sporadic concept (1)
- Fear (1)
- Fear Conditioning (1)
- Fear Extinction (1)
- Fehlerbeobachtung (1)
- Fehlererkennung (1)
- Fehlermonitoring (1)
- Fehlermonitoring (ERN) (1)
- Female (1)
- Flupentixol (1)
- Frühkindliche Katatonie (1)
- Frühkindlicher Hirnschaden (1)
- Functional Connectivity (1)
- Funktionelle Bildgebung (1)
- Funktionelle Kernspintomographie (1)
- Funktionelle Konnektivität (1)
- Furchtgeneralisierung (1)
- Fzd3 (1)
- G-protein inwardly rectifying potassium channel (1)
- G72 (1)
- GABBR1 (1)
- GAD1 (1)
- GAP (1)
- GFAP (1)
- GHQ-28 (1)
- GIRK 2 (1)
- GLRB (1)
- GPCRs (1)
- GRN (1)
- GWAS (1)
- Gauss Prozess Klassifikation (1)
- Gaussian Process Classification (1)
- Geistige Behinderung (1)
- Geistlicher Beruf (1)
- Gelelektrophorese (1)
- Gemeindepsychiatrie (1)
- Gen Polymorphismen (1)
- Gen Umweltinteraktion (1)
- Gen-Umwelt-Interaktion (1)
- Gen-Umwelt-Interaktionen (1)
- Gene by Environment (1)
- Genemutation (1)
- Generic questionnaire (1)
- Genetic (1)
- Genklonierung (1)
- Genomische Bildgebung (1)
- Genotype (1)
- Geriatrie (1)
- Gerontopsychiatrie (1)
- Geschlechtsunterschiede (1)
- Gewalt (1)
- Gewalttätigkeit (1)
- Gewicht (1)
- Glial fibrillary acidic protein (1)
- Gliogenese (1)
- Glucocorticosteroidrezeptor (1)
- Glucose (1)
- Glucosestoffwechsel (1)
- Glucosetransporter (1)
- Glutamat (1)
- Granular layer (1)
- Gray, Jeffrey Alan (1)
- Gyrus dentatus (1)
- HAND (1)
- HDBSCAN (1)
- HIV (1)
- HIV-Demenz (1)
- HIV-dementia (1)
- HRV (1)
- Habituationstraining (1)
- Handlung (1)
- Handlungsüberwachung (1)
- Haplotype (1)
- Heilberuf (1)
- Helfender Beruf (1)
- Hemmung (1)
- Herzfrequenz (1)
- Hirninfarkt (1)
- Hirnstimulation (1)
- Histochemie (1)
- Htr1a (1)
- Htr2a (1)
- Htr2c (1)
- Human CDH13 (1)
- Human behaviour (1)
- Human brain (1)
- Human entorhinal area (1)
- Humans (1)
- Huntington's disease . Human cerebral cortex (1)
- Hurst Exponent (1)
- Hyperintense Marklagerläsionen (1)
- Hyperintense white matter lesions (1)
- Hypertonie (1)
- Hypofrontalität (1)
- Hyponatriämie (1)
- Hämodialyse (1)
- I7 (1)
- ICT (1)
- IDCL-P (1)
- IMpACT (1)
- Iife threatening catatonic syndrome (1)
- Ile408Val-Polymorphismus (1)
- Imaging genomics (1)
- Imipramin (1)
- Immonology (1)
- Immunhistochemie (1)
- Immunologie (1)
- Immunparameter (1)
- Implizites Gedächtnis (1)
- Inanspruchnahme (1)
- Induced Pluripotent Stem Cells (1)
- Induzierte pluripotente Stammzelle (1)
- Inflammatio (1)
- Informationsverarbeitung (1)
- Insensitivity (1)
- Insulin Degrading Enzyme (1)
- Insulin resistance (1)
- Interaktion (1)
- Interaktionen (1)
- Interferon-alpha (1)
- Internationale Wernicke-Kleist-Leonhard-Gesellschaft (1)
- Interneuron (1)
- Japanese population (1)
- Jugendamt (1)
- Jurist (1)
- KCC3 (1)
- KCNJ6 (1)
- KCNN3 (1)
- KFZA (1)
- KIAA0027 (1)
- KIAA1646 (1)
- Kalium-Chlorid-Cotransporter 3 (1)
- Kaliumkanal (1)
- Kandidatengene (1)
- Kataphasie (1)
- Kernspintomografie (1)
- Kinder (1)
- Kindesmisshandlung (1)
- Klassifikations- und Regressionsbaum (1)
- Klinische Psychiatrie (1)
- Klonierung (1)
- Knock-out mice (1)
- Knockout-Maus (1)
- Koffein (1)
- Kognitive Kontrolle (1)
- Komorbidität (1)
- Konfliktverarbeitung (1)
- Kontusion (1)
- Konzentration (1)
- Kopienzahlvariation (1)
- Kopplungsanalyse (1)
- Kortikale Regulation (1)
- Kriminalität (1)
- Kulturberuf (1)
- Körpertherapie (1)
- Körperwahrnehmung (1)
- LPHN3 (1)
- LPS (1)
- Lamotrigin (1)
- Late Positive Potential (1)
- Latency (1)
- Lateralitity (1)
- Laterality (1)
- Lebendnierenspende (1)
- Lebendnierentransplantation (1)
- Lebensereignisse (1)
- Leo (1)
- Leonhard Klassifikation (1)
- Leonhard cIassification (1)
- Leonhard´s classification (1)
- Lernstrategien (1)
- Lernstrategien bei Geschlecht Fach Semester (1)
- Leuk (1)
- Leukoaraiose (1)
- Leukoaraiosis (1)
- Leukozyten (1)
- Liquor (1)
- Lithium (1)
- Locus coeruleus (1)
- Long-term depression (1)
- MAOA (1)
- MAPK signaling (1)
- MCPH1 (1)
- MIBG (1)
- MNS (1)
- MPH (1)
- MRT (1)
- Magnetische Resonanz (1)
- Maintenance treatment (1)
- Major depression (1)
- Malignant neuroleptic syndrome (1)
- Malignes neuroleptisches Syndrom (1)
- Mandelkernkomplex (1)
- Mania (1)
- Manie (1)
- Massage (1)
- Massagetherapie (1)
- Maternal infections (1)
- Measurement invariance (1)
- Media (1)
- Medicine (1)
- Memory dysfunction (1)
- Mensch (1)
- Messenger-RNA (1)
- Metaiodobenzylguanidine (1)
- Methylierung (1)
- MiMIC (1)
- Migraine (1)
- Migrationshintergrund (1)
- Mikrokernfrequenzanalyse (1)
- Mirror neuron system (1)
- Mismatch Negativity MMN (1)
- Mlc1 (1)
- Model (1)
- Modellierung (1)
- Moderator (1)
- Molecular biology (1)
- Molecular-genetics (1)
- Monoamine (1)
- Monoamine Oxidase/genetics (1)
- Monopolar depression (1)
- Mood disorders (1)
- Motor nerve biopsy (1)
- Motorischer Cortex (1)
- Motorisches System (1)
- Mouse-brain (1)
- Multimorbidität (1)
- Mutationsanalyse (1)
- Münchhausen by proxy (1)
- Münchhausen-Syndrom der Angehörigen (1)
- Mütter (1)
- N-Back-Test (1)
- N170 (1)
- N200 (1)
- NADPH-Dehydrogenase (1)
- NADPHd (1)
- NCAM1 (1)
- NEO PI-R (1)
- NMDA-Rezeptor (1)
- NMR-Tomographie (1)
- NO (1)
- NO-Synthetase (1)
- NOS (1)
- NOS-I knockout mice (1)
- NOS-I-Knockout-Mäuse (1)
- NOS1 (1)
- NOS1 ex1f-VNTR Polymorphismus (1)
- NOS1VNTR (1)
- NPU (1)
- NR3C1 (1)
- NSAID (1)
- Nah-Infrarot Reflexionsspektroskopie (1)
- Nahinfrarotspektroskopie (1)
- Nebenwirkung (1)
- Negative difference Nd (1)
- Neostriatum (1)
- Nerve fibers (1)
- Nesplora Aquarium (1)
- Neurobiologie (1)
- Neurodegeneration (1)
- Neurodevelopmental Disorder (1)
- Neurogenetik (1)
- Neuroimaging (1)
- Neuroinflammation (1)
- Neuroleptika (1)
- Neurologie (1)
- Neurolucida (1)
- Neuromelanin (1)
- Neuromorphologie (1)
- Neuronal plasticity (1)
- Neurone number (1)
- Neurons (1)
- Neuropathy (1)
- Neuropeptid S Rezeptor Gen (1)
- Neuropeptid Y (1)
- Neuropeptide Y (1)
- Neuroplasticity (1)
- Neuroprotection (1)
- Neuropsychiatrie (1)
- Neuropsychologie (1)
- Neurotrophic factors (1)
- Neurotrophine (1)
- Neurowissenschaften (1)
- Nicht-Suizid-Vertrag (1)
- Niereninsuffizienz (1)
- Nissl stain (1)
- Nitric oxide (1)
- Nitric oxide synthase (1)
- NoGo-P300 (1)
- Npy (1)
- Npyr1 (1)
- Npyr2 (1)
- Nucleus accumbens (1)
- Ontogeny (1)
- Operante Konditionierung (1)
- Opioid receptor (1)
- Oppositionelle Störung (1)
- Orexin (1)
- Orexin-/Hypocretin- Rezeptor-1 (HCRTR1)-Gen (1)
- Orexin-System (1)
- Oxidative Stress (1)
- Oxidativer Stress (1)
- Oxytocin (1)
- P100 (1)
- P150 (1)
- P300 topography (1)
- PAX genes (1)
- PAX-7 (1)
- PAX-Gene (1)
- PET-1 (1)
- PLC (1)
- PTSD (1)
- PYY3-36 (1)
- Paarbindungsverhalten (1)
- Panic Disorder/genetics (1)
- Panic Disorder/therapy (1)
- Panikerkrankung (1)
- Pannexin (1)
- Parallel fiber synapses (1)
- Paranoide Schizophrenie (1)
- Paraphrenie <Schizophrenie> (1)
- Parkinson (1)
- Pathogenese (1)
- Patienten (1)
- Patientenklassifikation (1)
- Perinatal Asphyxia (1)
- Perinatal brain damage (1)
- Periodische Katatonie (1)
- Peristenz (1)
- Periventricular hyperintensities (1)
- Periventrikuläre Hyperintensitäten (1)
- Personalized medicine (1)
- Persönlichkeitsstörungen (1)
- Persönlichkeitstheorie (1)
- Persönlichkeitsveränderung (1)
- Pharmakoepigenetik (1)
- Pharmakogenetik (1)
- Pharmakovigilanz (1)
- Phasic Fear (1)
- Photon migration (1)
- Physikalische Therapie (1)
- Physiological functions (1)
- Phänotypen (1)
- Pigmentarchitectonics (1)
- Plasma Level (1)
- Polarity index (1)
- Polygener Risikoscore (1)
- Polymo (1)
- Polymorphismen (1)
- Polytoxikomanie (1)
- Poststroke depression (1)
- Predominant polarity (1)
- Prefrontalt Cortex (1)
- Pregnancy (1)
- Prevention (1)
- Primaten (1)
- Primärprävention (1)
- Prognostic markers (1)
- Progranulin (1)
- Promotor <Genetik> (1)
- Propagation (1)
- Prosaccade (1)
- Prosoziales Verhalten (1)
- Prädiabetes (1)
- Prädiktor (1)
- Prädiktoren (1)
- Präfrontaler Kortex (PFC) (1)
- Prävention Prüfungsangst (1)
- Prüfungsangst (1)
- Psychiatrische Versorgung (1)
- Psychisch Kranker (1)
- Psychische Störung (1)
- Psychogalvanische Reaktion (1)
- Psychologie (1)
- Psychoneuroimmunologie (1)
- Psychopathology (1)
- Psychopharmakatherapie (1)
- Psychopharmakotherapie (1)
- Psychotherapie (1)
- Punktmutation (1)
- Purkinje-Zellen (1)
- Putamen (1)
- Pyramidenzelle (1)
- Pädagogischer Beruf (1)
- QE (1)
- QT-Verlängerung (1)
- QT-prolongation (1)
- QTc prolongation (1)
- QTc-Verlängerung (1)
- QTc-Zeit (1)
- QTc-Zeit Verlängerung (1)
- Qb-Test (1)
- Quantitative Anatomie (1)
- Querschnittsanalyse (1)
- Quetiapin (1)
- Quetiapine (1)
- RFLP (1)
- RIM1α (1)
- RNA Sequencing (1)
- RNA expression (1)
- RSK (1)
- RTMS (1)
- Raphe (1)
- Rat-brain (1)
- Regional differences (1)
- Regulator of G protein signaling 2 (1)
- Rehaklinik (1)
- Reliabilität (1)
- Reproduzierbarkeit (1)
- Resilienz (1)
- Resting-EEG (1)
- Restraint stress (1)
- Rezeptor (1)
- Rgs2 (1)
- Risikofaktor (1)
- Risikofaktoren (1)
- Riskanter Alkoholkonsum (1)
- Rotary EXcitation (REX) (1)
- Roux-en-Y gastric bypass surgery (1)
- Ruhe-EEG (1)
- Ruhebedingungen (1)
- S-HT (1)
- S6KII RSK (1)
- SARS-CoV-2 (1)
- SAT (1)
- SCF (1)
- SHANK3 (1)
- SIV (1)
- SKP1 (1)
- SLC6A4 (1)
- SMARCA2 (1)
- SNAP-25 (1)
- SNRI (1)
- SPAN (1)
- SSRI (1)
- STORM (1)
- SV pool (1)
- SV2C ADHD (1)
- SV2C ADHS (1)
- Saccadic eye-movements (1)
- Scattering (1)
- Schizoaffektive Psychose (1)
- Schizophrenieerkrankung (1)
- Schreckreflex (1)
- Schwangerschaftsinfektion (1)
- Secondary affective disorder (1)
- Sekundärkrankheit (1)
- Selbstmord (1)
- Selbstwirksamkeit (1)
- Selective attention (1)
- Senescent rat (1)
- Senile rat (1)
- Senile rats (1)
- Sensory Gating (1)
- Sequence Analysis (1)
- Serotonerges System (1)
- Serotonin transporter polymorphism (1)
- Serotonin-Reuptake-Hemmer (1)
- Serotonin-Transporter-Gen (1)
- Serotonin-Transporter-Polymorphism (1)
- Serotonine transporter (1)
- Serotoninrezeptor (1)
- Sert-deficient mice (1)
- Sertralin (1)
- Serum (1)
- Set Shifting (1)
- Setshifting (1)
- Sexualität (1)
- Siekiera (1)
- Skin biopsy (1)
- Skin conductance (1)
- Small RNA (1)
- Social Buffering (1)
- Social Distancing (1)
- Social buffering (1)
- Social interaction (1)
- Somatosensibel evozierte Potentiale des N. vagus (1)
- Somatosensibel evozierte Potenziale des Nervus vagus (1)
- Somatosensibel-evozierte Potentiale des N. Vagus (1)
- Somatosensory evoked potentials of N. vagus (1)
- Sonic hedgehog (1)
- Sozial evaluative Situation (1)
- Sozialberuf (1)
- Sozialdienst (1)
- Soziale Arbeit (1)
- Soziale Interaktion (1)
- Sozialer Kontakt (1)
- Sozialer Stress (1)
- Specific Phobia (1)
- Spectroscopy fnirs (1)
- Spezifische Phobien (1)
- Spiegelneuron (1)
- Spiegelneuronensystem (1)
- Spinal nerves (1)
- Spines (1)
- Spinnenphobie (1)
- Spontan Hypertensive Ratte (1)
- Stationäre psychiatrische Versorgung (1)
- Stereotaxie (1)
- Stereotaxy (1)
- Stimmungsstabilisator (1)
- Stimuli (1)
- Stoppsignal (1)
- Strain differences (1)
- Striatum (1)
- Stroop (1)
- Studienerfolg und Prüfungsangst (1)
- Störung (1)
- Störung des Sozialverhaltens (1)
- Sub-saharan Africa (1)
- Sucht (1)
- Suchtreize (1)
- Suchtreizreaktivität (1)
- Sugar (1)
- Suizid (1)
- Suizidalität (1)
- Suizidversuch (1)
- Superoxiddismutase (1)
- Superoxide dismutase (1)
- Surrogate endpoints (1)
- Sustained Fear (1)
- System (1)
- Systematic review (1)
- Systematik (1)
- Systematische Paraphrenie (1)
- T-cadherin (1)
- TDM (1)
- TMS (1)
- TPH (1)
- TPH2 gene (1)
- TPQ (1)
- Task-performance (1)
- Temporal predictability (1)
- Testgütekriterium (1)
- Thalamic nuclei (1)
- Therapeutic Drug Monitoring (1)
- Therapeutic drug monitoring (1)
- Therapeutisches Drug monitoring (1)
- Therapie (1)
- Theta Burst Stimulation (1)
- Thrombozyt (1)
- Tinnitus (1)
- Tissues (1)
- Toll-like receptor 4 (TLR4) (1)
- Trailmaking Test (1)
- Transcranial Magnetic Stimulation (1)
- Transgenic mice (1)
- Transkranielle Magnetstimulation (1)
- Transkranielle Magnetstimulation (TMS) (1)
- Transkriptionsfaktor (1)
- Transkutane Vagusnervstimulation (1)
- Transkutane elektrische Nervenstimulation (1)
- Transporter (1)
- Trauma (1)
- Trennungsangst (1)
- Triple in situ hybridization (1)
- Tryptophan hydroxylase-2 (Tph2) (1)
- Tryptophanhydroxylase 2 (1)
- UPPS (1)
- Ultrastructure (1)
- Unc-13 (1)
- VAL66MET polymorphism (1)
- VBM (1)
- VITA Studie (1)
- VITA study (1)
- VSEP (1)
- Vagus-somatosensorisch evozierte Potentiale (1)
- Vagusevozierte Potentiale (1)
- Val158Met-COMT-Polymorphismus (1)
- Valproat (1)
- Valproinsäure (1)
- Vasopressin receptor gene (1)
- Vasopressinrezeptorgen (1)
- Verbal Flue (1)
- Vergence (1)
- Verhalten (1)
- Vigilanz (1)
- Vitamin D (1)
- Vitamin-D-Mangel (1)
- Voluntary control (1)
- Vorhersagbarkeit (1)
- WURS (1)
- Warburg-Effect (1)
- Western diet (1)
- Wirkmechanismus (1)
- Wortflüssigkeitstest (1)
- Würzburg / Institut für Humangenetik (1)
- Würzburger Adipositas Studie (1)
- Xenopus laevis oocytes (1)
- Zahnbehandlungsphobie (1)
- Zellkultur (1)
- Zerebraler Insulinmetabolismus (1)
- Zusammenhang Lernstrategien (1)
- Zuweisung (1)
- Zwangsstörung (1)
- Zykloide Psychose (1)
- aVNS (1)
- abstinence (1)
- accidents (1)
- acetylcholine (1)
- acid sphingomyelinase (1)
- acoustic startle (1)
- acoustic startle reflex (1)
- acute brain slices (1)
- acute mania (1)
- acute stress (1)
- adenosine (1)
- adolescence (1)
- adult Neurogenesis (1)
- adult attention deficit/hyperactivity disorder (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adult treatment (1)
- adulte ADHS (1)
- adulte neurogenese (1)
- adultes ADHS (1)
- adulthood (1)
- adults (1)
- adverse drug reactions (1)
- advisory groups (1)
- affect-laden paraphrenia (1)
- affective state (1)
- affektvolle Paraphrenie (1)
- age stereotypes (1)
- aggressiveness (1)
- aging and cell death (1)
- aging brain (1)
- aging-related disease (1)
- agoraphobia (1)
- agreeableness (1)
- akustisch evozierte Potentiale (1)
- akut lebensbedrohlich katatones Syndrom (1)
- alcohol addiction (1)
- alcohol dependance (1)
- alcohol dependency (1)
- alcoholism (1)
- allocation (1)
- allostatic load (1)
- ambulante psychotherapeutische Versorgung (1)
- amino acid analysis (1)
- amitriptyline (1)
- amygdala response (1)
- analysis of variance (1)
- animal performance (1)
- anti-depressive treatment (1)
- anti-suicide-contract (1)
- anticipation (1)
- anticipatory anxiety (1)
- antidepressant drug (1)
- antidepressive Therapie (1)
- antidepressive agents (1)
- antipsychotics (1)
- anxiety like (1)
- anxiety-like behavior (1)
- aphasia (1)
- apolipoprotein (1)
- apolipoprotein-E4 (1)
- apoptosis (1)
- appetitive Reaktionstendenzen (1)
- assay (1)
- assessment of cognitive disorders/dementia (1)
- association studies (1)
- atlas‐based volumetry (1)
- atopic dermatitis (1)
- attention (1)
- attention deficit hyperactivity disorder (1)
- attention deficit/hyperactivity disorder (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- attentional blink (1)
- atypical antipsychotic (1)
- auditory cortex (1)
- auditory evoked potentials (1)
- auricular vagusnervstimulation (1)
- aurikuläre Vagusnervstimulation (1)
- autism (1)
- autism spectrum disorder (1)
- autism-like behavior (1)
- autoinhibition (1)
- awareness (1)
- axonal transport (1)
- basal ganglia (1)
- bdnf (1)
- behavioral activation system (1)
- beside test (1)
- biased signaling (1)
- bipolar (1)
- bipolar affektive Erkrankung (1)
- bipolar disorders (1)
- bipolar-affektive Erkrankung (1)
- bipolare (1)
- bipolare Erkrankung (1)
- bipolare Störung (1)
- bleeding (1)
- blood biomarker (1)
- body awareness (1)
- bold (1)
- bold activity (1)
- brain activation (1)
- brain derived neurotrophic factor (1)
- brain development (1)
- brain disorders (1)
- brain insulin system (1)
- brain stimulation (1)
- brain-regions (1)
- breast cancer (1)
- burden (1)
- cAMP (1)
- cadherin (1)
- cadherins (1)
- caffeine (1)
- caffeine-induced anxiety (1)
- cancer (1)
- candidate genes (1)
- capacity (1)
- capecitabine (1)
- cardiac sympathetic nerve system (1)
- cardiovascular arousal (1)
- case fatality rates (1)
- cataphasia (1)
- catechol-O-methyltransferase (1)
- cell culture (1)
- cell membranes (1)
- cell proliferation (1)
- cells (1)
- ceramides (1)
- cerebellar ataxia (1)
- cerebellar atrophy (1)
- cerebral artery occlusion (1)
- cerebrospina (1)
- character items (1)
- child development (1)
- child memory (1)
- childhood maltreatment (1)
- cholinergic neurons (1)
- chromosome 12 (1)
- chronic distress (1)
- chronic hemodialysis (1)
- chronic stress (1)
- chronical stress (1)
- chronischer Stress (1)
- classical conditioning (1)
- classification (1)
- clinical diagnosis (1)
- clinical practice guideline (1)
- clinical trial (1)
- coagulation (1)
- coexpression (1)
- cognitive bias (1)
- cognitive deficits (1)
- cognitive neuropsychology in dementia (1)
- cognitive-behavioral therapy (1)
- cognitive-behavioural psychotherapy (1)
- cohort studies (1)
- community sample (1)
- comparative anatomy (1)
- complementary alternative medicine (1)
- complex interventions (1)
- comprehensive psychosomatic assessment (1)
- computer-assisted instruction (1)
- concentration (1)
- conditioning (1)
- conduct disorder (1)
- conflict detection (1)
- conflict processing (1)
- congenital heart-deffects (1)
- contextual fear conditioning (1)
- continuous performance test (1)
- control strain (1)
- coping style (1)
- coping with challenge (1)
- copy number variants (1)
- copy number variation (1)
- copy-number variation (1)
- corpus striatum (1)
- cortex (1)
- corticotropin releasing factor (1)
- cortisol (1)
- course (1)
- cross-sectional analysis (1)
- cross-sectional studies (1)
- cross-sectional study (1)
- crystal structure (1)
- cue-incuded craving (1)
- cue-induced craving (1)
- cytoarchitectonic maps (1)
- cytoarchitectonics (1)
- cytome biomarkers (1)
- damage (1)
- data mining (1)
- de-novo methylation (1)
- deaths (1)
- decision making (1)
- decision making process (1)
- defensive reactivity (1)
- defensive system reactivity (1)
- deficient mice (1)
- deficit (1)
- deficit hyperactivity disorder (1)
- dehydrogenases (1)
- delay (1)
- deletion (1)
- delinquency (1)
- dementia with Lewy bodies (1)
- dental phobia (1)
- depressive Störung (1)
- depressive Symptome (1)
- depressive episode (1)
- depressive symptoms (1)
- detoxification (1)
- development (1)
- developmental delay (1)
- dexamethasone (1)
- diagnosis (1)
- diagnostic medicine (1)
- dictator game (1)
- diet (1)
- differentiation (1)
- digital phenotyping (1)
- dimensions (1)
- disability (1)
- discrimination training (1)
- disease modelling (1)
- disease-modifying therapies (1)
- distraction (1)
- diuretic (1)
- dlPFC (1)
- dopamin (1)
- dopamine D2 receptor gene (1)
- dopamine melanin (1)
- dopaminergics (1)
- dorsal raphe nucleus (1)
- dorsolateral (1)
- dorsolateraler Präfrontalkortex (1)
- dorsolateraler präfrontaler Cortex (1)
- dorsolateraler präfrontaler Kortex (1)
- dot-probe (1)
- drift-diffusion model (1)
- drift-diffusion modeling (1)
- drug development (1)
- drug metabolism (1)
- drug monitoring (1)
- drug-addiction (1)
- drug-drug interaction (1)
- dual guidance (1)
- duplication (1)
- dysbindin (1)
- e-learning (1)
- eNOS (1)
- early detection (1)
- early diagnosis (1)
- early intervention (1)
- early-onset predictors (1)
- ecological momentary assessment (1)
- ectodomain cleavage (1)
- egoism (1)
- elderly (1)
- electrode recording (1)
- electroeneephalography (1)
- electron tomography (1)
- embodiment (1)
- embryos (1)
- emotional (1)
- emotional Stroop-test (1)
- emotional behavior (1)
- emotional experience (1)
- emotional influence (1)
- emotional information (1)
- emotional interference (1)
- emotional processing (1)
- emotionale Interferenz (1)
- emotionale Verarbeitung (1)
- emotionaler Stroop-Test (1)
- emotions (1)
- encephalitis lethargica (1)
- endocannabinoids (1)
- endogenous psychoses (1)
- energy expenditure (1)
- energy metabolism (1)
- entorhinal cortex (1)
- environment (1)
- enzymatic synthesis (1)
- epigenetics in the nervous system (1)
- epigenomics (1)
- error monitoring (1)
- error positivity (1)
- error processing (1)
- error-positivity (Pe) (1)
- error-related negativity (ERN) (1)
- escitalopram (1)
- estrogen receptor gene polymorphism (1)
- event-related fMRI (1)
- event-related potentials (ERP) (1)
- executive function training (1)
- exekutive Funktion (1)
- exekutive Funktionen (1)
- experimentelle Denkprüfung (1)
- exposition training (1)
- exposure therapy (1)
- exposure treatment (1)
- eyes (1)
- fMRT (1)
- facial affect (1)
- facial expression (1)
- facticious disorder (1)
- factor expression (1)
- famiIiaI ·sporadic concept (1)
- familial-sporadic concept (1)
- families (1)
- family (1)
- family caregivers (1)
- family-based association study (1)
- fatigue (1)
- fear expression (1)
- fear learning (1)
- fear memory consolidation (1)
- fear-relevant training (1)
- febrile seizures (1)
- feedback (1)
- female (1)
- ferroptosis (1)
- fetal preconditioning (1)
- fibromyalgia syndrome (1)
- fluid (1)
- fmri activity (1)
- follow-up (1)
- formal thought disorder (1)
- formale Denkstörung (1)
- freezing (1)
- frontal cortex (1)
- frontotemporal lobar degeneration (1)
- fumarate (1)
- functional resting-state connectivity (1)
- funktionelle Magnetresonanztomographie (1)
- funktionelle Nah-Infrarot Spektroskopie (1)
- funktionelle Nahinfrarotspektroskopie (1)
- funktionelle Nahinfrarotspektroskopie (fNIRS) (1)
- funktionelle Resting-State Konnektivität (1)
- fusiform gyrus (1)
- gender (1)
- gender differences (1)
- gene analysis (1)
- gene environment (1)
- gene environment interaction (1)
- gene polmorphism (1)
- gene × gene interaction (1)
- gene-by-environment interaction (1)
- gene-environment interaction (1)
- geneexpression (1)
- genetic interaction (1)
- genetic loci (1)
- genetic phenotypes (1)
- genetic risk factor (1)
- genetic variants (1)
- genetic variation (1)
- genetics memory (1)
- genome-wide (1)
- genomic organization (1)
- genomic response (1)
- genomische Bildgebung (1)
- genotype (1)
- genotype-phenotype patterns (1)
- glia (1)
- glucocorticoids (1)
- glucose (1)
- glucose tolerance (1)
- glutamate receptor (1)
- glycine (1)
- glycine receptor (1)
- glycine receptor beta subunit (1)
- glycogen synthase kinase-3β (1)
- granule cells (1)
- granules (1)
- growth factor (1)
- hand (1)
- haplotypanalysis (1)
- haplotype (1)
- haplotypeanalysis (1)
- haplotypes (1)
- head (1)
- heart failure (1)
- heat shock protein Hsc-70 (1)
- heavy user (1)
- hepcidin (1)
- heritability (1)
- heterosis (1)
- heterozygote (1)
- hierarchical drift-diffusion modeling (1)
- high-pressure freezing (1)
- hippocampal formation (1)
- hippocampal mossy fiber bouton (1)
- hippocampal neurogenesis (1)
- hippocampal volume (1)
- histamine (1)
- hospital (1)
- hospitalisation (1)
- human behaviour (1)
- human brain (1)
- human induced pluripotent stem cell (hiPSC) (1)
- human orbitofrontal cortex (1)
- hyperactivity (1)
- hypofrontality (1)
- hyponatremia (1)
- hypothalamic gene expression (1)
- iPSC (1)
- iPSCs (1)
- iTBS (1)
- iiron transporter (1)
- imaging genetics (1)
- imaging mass spectrometry (1)
- imipramine (1)
- immediate-early gene (1)
- immunology (1)
- impact (1)
- impairments (1)
- impulse control disorders (1)
- in vivo (1)
- incentives (1)
- incidence (1)
- indans (1)
- individual differences (1)
- individual quality of life (1)
- inferior frontal gyrus (1)
- inferior parietal lobule (1)
- inflammatory cytokines (1)
- inflammatory diseases (1)
- informal caregiving (1)
- information processing (1)
- inhibition (1)
- insulin resistance (1)
- insulin-like growth factor 1 receptor (1)
- intelligibility (1)
- interleukin 6 (1)
- intermediate phenotype approach (1)
- interstitial duplications (1)
- intervention study (1)
- iron in parkinsonism (1)
- iron model (1)
- iron pathology (1)
- ischemic brain injury (1)
- ischemic stroke (1)
- joint action (1)
- joint-action (1)
- judgement bias (1)
- kaliumchlorid cotransporter (1)
- kindliche Traumatisierung (1)
- klinische Verlaufsparameter (1)
- knock-out mice (1)
- knockout-mice (1)
- kognitive Leistungen (1)
- kombinierte Untersuchung (1)
- laboratory and online studies (1)
- laboratory environment (1)
- lacking (1)
- learning and memory (1)
- learning curves (1)
- learning strategies (1)
- length of stay (1)
- lethai catatonia (1)
- levodopa (1)
- life (1)
- life stress (1)
- linkage (1)
- linkage analysis (1)
- liraglutide (1)
- living kidney donation (1)
- localization microscopy (1)
- loci (1)
- locomotor activity (1)
- loneliness (1)
- longitudinal magnetic resonance imaging (1)
- mIBG (1)
- machine learning (1)
- magnetic-resonance-spectroscopy (1)
- major depressive disorder (MDD) (1)
- mammalian development (1)
- management (1)
- manisch-depressive Störung (1)
- mapping susceptibility genes (1)
- massagetherapy (1)
- massively multiplayer online role playing games (1)
- maternal (1)
- maternal infection (1)
- maternal separation (1)
- matrix metalloproteinase (1)
- maturation (1)
- mechanismofaction (1)
- mechanisms (1)
- medial prefrontal cortex (mPFC) (1)
- medial temporal lobe (1)
- median and dorsal raphe (1)
- medical Education (1)
- medical education (1)
- medicine (1)
- megalencephalic leucoencephalopathy (1)
- membrane potential (1)
- membrane proteins (1)
- memory consolidation and extinction (1)
- memory deficits (1)
- memory formation (1)
- mental arithmetic (1)
- mental illness (1)
- messenger RNA (1)
- metaanalysis (1)
- metagenomics (1)
- methylation (1)
- methylphenidate (1)
- miRNS (1)
- microRNA (1)
- microarray (1)
- microarrays (1)
- microcephalin 1 (1)
- microdeletion (1)
- micronucleus test (1)
- midbrain (1)
- middle aged (1)
- migration background (1)
- mind-body intervention (1)
- mismatch (1)
- mismatch negativity (MMN) (1)
- mitochondria (1)
- mitochondrial pathology (1)
- mitochondrial translation (1)
- mitochondrial transport (1)
- mobile crowdsensing (1)
- mobile health (1)
- moclobemide (1)
- modifizierter Dexamethason-Suppressions-Test (1)
- modulation (1)
- molecular genetics (1)
- monetary incentive delay task (1)
- monoamine (1)
- monoamine oxidase A (1)
- monoamine oxidase inhibitors (1)
- monoamine transporters (1)
- monopolar depressive disorders (1)
- monopolare endogene Depression (1)
- mood disorder (1)
- mood disorders (1)
- mood stabilizer (1)
- morality (1)
- morphological classification (1)
- morphologische Klassifikation (1)
- mother (1)
- mothers (1)
- motivation (1)
- motoneuron (1)
- mrsk2 KO mouse (1)
- multicenter (1)
- multimedia, (1)
- multiple myeloma (1)
- multiple system atrophy (1)
- multi‑center cohort study (1)
- munchhausen by proxy (1)
- murine gene (1)
- murines Gen (1)
- musculus temporalis (1)
- mutation analysis (1)
- myocardial sympathetic innervation imaging (1)
- nNOS (1)
- nanoarchitecture (1)
- near-infrared spectroscopy (NIRS) (1)
- negative difference (Nd) (1)
- negative priming (1)
- negatives Priming (1)
- neonatal brain (1)
- neonatal hypoxia (1)
- nervour system (1)
- nervous system (1)
- neural activity (1)
- neural fear network activation (1)
- neural mechanisms (1)
- neural stem cells (1)
- neuregulin-1 (1)
- neurite outgrowth (1)
- neurobiology (1)
- neurodevelopmental disorders (1)
- neurodevelopmental disorders / genetics (1)
- neurofilament light chain (1)
- neurological disorders (1)
- neurolucida (1)
- neuromelanin granules (1)
- neuromorphology (1)
- neuromuscular junction (1)
- neuron (1)
- neuron navigator 3 (1)
- neuronal dendrites (1)
- neuronal differentiation (1)
- neuronal dysfunction (1)
- neuronal plasticity (1)
- neuronale NO-Synthase (1)
- neuronale NOS (1)
- neurons (1)
- neuropathic pain (1)
- neuropeptide S receptor gene (1)
- neuroplasticity (1)
- neuropsychiatry (1)
- neurorehabilitation (1)
- neurothrophic factor (1)
- neurotransmitter (1)
- neurotrophic factor (1)
- neurotrophic factor gene (1)
- neurotrophins (1)
- nicht-invasive Vagusnervstimulation (1)
- niederfrequente Oszillationen (1)
- nitric oxide (1)
- nitricoxidesynthase (1)
- no-suicide-contract (1)
- non-steroidal anti-inflammatory drug (1)
- nortriptyline (1)
- nucleus (1)
- nucleus accumbens (1)
- nurses (1)
- object and spatial visual working memory (1)
- objective structured clinical examination (1)
- observer agreement (1)
- obstetric complications (1)
- occupancy (1)
- of-the-literature (1)
- old age depression (1)
- older employees (1)
- onset (1)
- optic ataxia (1)
- oral anticancer drugs (1)
- organische affektive Störungen (1)
- oscillating biomagnetic fields (1)
- oxidativer Stress (1)
- oxygen consumption (1)
- pair bonding (1)
- panx1 (1)
- panx2 (1)
- panx3 (1)
- parathyroid hormone 1 receptor (1)
- parent training (1)
- parental origin (1)
- parietal lobe (1)
- parkinson’s disease (1)
- paternal (1)
- patient-doctor-relationship (1)
- patients (1)
- pediatrics (1)
- people (1)
- perception (1)
- periodische Katatonie (1)
- peripartale psychische Erkrankungen (1)
- peripheral-blood lymphocytes (1)
- perniziöse Katatonie (1)
- persistence (1)
- persistent ADHD (1)
- personality disorders (1)
- personality traits (1)
- personalized medicine (1)
- perspectives (1)
- pharmacogenetics (1)
- pharmacokinetic (1)
- pharmacology (1)
- phasic threat responding (1)
- phenelzine (1)
- phobia (1)
- phosphorylated tau protein (1)
- physical health (1)
- physiology (1)
- physiotherapy (1)
- pigment (1)
- plasma levels (1)
- polymophismus (1)
- population (1)
- population-based studies (1)
- positive affect (1)
- positive interneurons (1)
- positron-emission-tomography (1)
- post error slowing (1)
- postencephalitic parkinsonism (1)
- posterior cortical atrophy (1)
- posterior parietal cortex (1)
- posteroinferior occipitotemporal gyrus (1)
- postmortem (1)
- postnatal depression (1)
- posttraumatic-stress-disorder (1)
- potassium chlorid co-transporter (1)
- precision medicine (1)
- predict (1)
- predictors (1)
- prefrontal (1)
- prefrontal Cortex (1)
- prefrontal oxygenation (1)
- pregnancy anxiety (1)
- prepulse inhibition (1)
- presynaptic (1)
- presynaptic homeostasis (1)
- prevalence (1)
- prevention (1)
- prevention test anxiety (1)
- preventive strategies (1)
- primary care (1)
- primary progressive aphasia (1)
- primary response genes (1)
- primates (1)
- process evaluation (1)
- processing bias (1)
- processing speed (1)
- proliferation (1)
- promoter (1)
- promoter region (1)
- prophylactic lithium (1)
- prosociality (1)
- protein (1)
- protein aggregation (1)
- protein kinase (1)
- präfrontal (1)
- präfrontale (1)
- präfrontale Oxygenierung (1)
- pränataler Stress (1)
- psychiatric psychotherapeutic care (1)
- psychiatric-hospitalization (1)
- psychiatrisch psychotherapeutische Versorgung (1)
- psycho-geriatrics (1)
- psychogeriatrics (1)
- psychological distress (1)
- psychological stress (1)
- psychooncology (1)
- psychopharmacotherapy (1)
- psychosocial workplace risk assessment (1)
- psychosozialer Stress (1)
- psychotic experiences (1)
- psychotropic medication (1)
- psychotropic medications (1)
- punishment (1)
- qtc (1)
- qualitative Studie (1)
- qualitative approaches (1)
- qualitative study (1)
- quality assurance (1)
- quality of live (1)
- quantitative anatomy (1)
- rTMS (1)
- randomized-controlled trial (1)
- ranskranielle magnetische Stimulation (1)
- rare diseases (1)
- rare mendelian disorders (1)
- rasagiline (1)
- rat brain (1)
- rating scale (1)
- reactivity (1)
- real-life interaction (1)
- realist evaluation (1)
- receptor (1)
- receptor gene polymorphism (1)
- receptors (1)
- reciprocity (1)
- recognition memory (1)
- reconsolidation (1)
- reconstruction (1)
- recurrent Tako-Tsubo cardiomyopathy (1)
- regenerative research (1)
- reinforcement learning theory (1)
- religiosity (1)
- remitted/acute phase (1)
- renal function (1)
- repair (1)
- repulsive guidance molecule A (1)
- research errors (1)
- resilience (1)
- resting-state fMRI (1)
- reward (1)
- reward deficiency syndrome (1)
- right inferior frontalgyrus (1)
- risk factor (1)
- risk genes (1)
- risperidone (1)
- rodent model (1)
- rule discovery (1)
- safety (1)
- safety behavior (1)
- sample size calculation (1)
- schizophrenic patients (1)
- schizophrenie (1)
- sections (1)
- selegiline (1)
- self-employed (1)
- sequence variations (1)
- serotonerge Aktivität (1)
- serotonerge Gene (1)
- serotonergic activity (1)
- serotonergic system (1)
- serotonin receptor (1)
- serotonin receptors (1)
- serotonin transporter deficient mice (1)
- serotonin(1A) receptor (1)
- serotonin-specific neurons (1)
- serotonin-transporter (1)
- sex (1)
- short-term methylphenidate brain (1)
- short-term-memory (1)
- sialic acid (1)
- sialyltransferase (1)
- signal transduction pathway (1)
- simulation (1)
- single subject (1)
- skin conductance (1)
- skin conduction response (1)
- small business (1)
- smoking cessation (1)
- social anxiety (1)
- social avoidance (1)
- social capital (1)
- social cognitive (1)
- social distancing (1)
- social experience (1)
- social isolation (1)
- social motives (1)
- social neuroscience (1)
- somatische Befunde (1)
- spastic (1)
- spatial memory (1)
- specific phobia (1)
- spectrum disorder (1)
- spectrum disorders (1)
- spezifische Phobie (1)
- sphingolipids (1)
- spontaneously hypertensive rat (1)
- spontaneously hypertensive rats (1)
- sporadic Parkinson's disease (1)
- startle reaction (1)
- states (1)
- stem cells (1)
- stereology (1)
- stimulation (TMS) (1)
- stop signal (1)
- strategies (1)
- stress granules (1)
- stressful life events (1)
- striatum (1)
- stroop interference (1)
- subphenotypes (1)
- subsctraction (1)
- subsequent memory (1)
- suicide (1)
- suicide attempt (1)
- supervisors (1)
- surrogate endpoints (1)
- survey (1)
- susceptibility (1)
- susceptibility genes (1)
- sustained threat responding (1)
- swim test (1)
- symptoms (1)
- synapse (1)
- synapse formation (1)
- synaptic plasticity (1)
- synaptic transmission (1)
- synaptic ultrastructure (1)
- synaptosomal-associated protein SNAP-25 (1)
- synaptosomal-assoziiertes Protein (1)
- synaptosomes (1)
- systematic paraphrenia (1)
- systems (1)
- tVNS (1)
- tandem mass spectrometry (1)
- targeted bisulfite sequencing (1)
- task complexity (1)
- task difficulty (1)
- tauopathy (1)
- tdcs (1)
- teaching hospital (1)
- telomere length (1)
- temporal lobe epilepsy (1)
- temporo-parietal junction (1)
- test anxiety (1)
- thalamus (1)
- theranostic markers (1)
- theta burst stimulation (1)
- threat-related stimuli (1)
- tinnitus (1)
- tolerability (1)
- tolerance (1)
- topographic analysis (1)
- topographische EEG-Analyse (1)
- trail making test (1)
- transcranial Direct Current Stimulation (tDCS) (1)
- transcranial magnetic (1)
- transcranial magnetic stimulation (1)
- transcranial magnetic stimulation (TMS) (1)
- transcutaneous vagusnervstimulation (1)
- transient global ischemia (1)
- transkranielle Gleichstomstimulation (1)
- transkranielle Gleichstromstimulation (tDCS) (1)
- transkutane Vagusnervstimulation (1)
- transmission (1)
- transporter gene SLC2A3 (1)
- tranylcypromine (1)
- treatment (1)
- treatment guidelines (1)
- treatment response (1)
- triplet repeats (1)
- tryptophan hydroxylase 2 (1)
- tryptophan hydroxylase-2 (1)
- ubiquitination (1)
- ultra-high risk (1)
- ultrasound imaging (1)
- understaffed (1)
- unerwünschte Arzneimittelwirkungen (1)
- unsystematic paraphrenia (1)
- unsystematische Paraphrenie (1)
- use (1)
- vagus somatosensory evoked potentials (1)
- vagus-evoked potentials (1)
- valence framing (1)
- validation (1)
- validity (1)
- vbm (1)
- ventromedial prefrontal cortex (1)
- verbal fluency (1)
- verbal fluency tasc (1)
- verbal fluency task (1)
- verbal fluency test (1)
- verbal n-back (1)
- verursachende Person (1)
- vesicular monoamine transporter (1)
- vesikulärer Monoamintransporter (1)
- victims (1)
- video-game (1)
- violence (1)
- virtual patients (1)
- viruses (1)
- virus–iron interaction (1)
- visuell-bildliches Arbeitsgedächtnis (1)
- visuell-räumliches Arbeitsgedächtnis (1)
- vitamin D deficiency (1)
- vitamin d (1)
- volumetric MRI (1)
- von Economo (1)
- voxel-based morphometry (1)
- wahrnehmen (1)
- weight (1)
- withdrawal (1)
- work-related stress (1)
- world of warcraft (1)
- yoga (1)
- younger employees (1)
- Ältere Rehabilitanden (1)
- Östrogenrezeptor-Polymorphismen (1)
- ɑ-Synuclein and iron (1)
Institute
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (467) (remove)
Sonstige beteiligte Institutionen
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (2)
- Department of Nuclear Medicine, Kanazawa University (1)
- Institut für Biopsychologie, Universität Dresden (1)
- Institut für Neurowissenschaften der Universität Mailand (1)
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Würzburg (1)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (1)
- Johns Hopkins University School of Medicine (1)
- Maastricht University, Department of Psychiatry and Neuropsychology (1)
- Translationale soziale Neurowissenschaften (1)
ResearcherID
- N-8985-2015 (1)
Auswirkungen der Genpolymorphismen ASIC1, BDNF und NPSR1 auf die Antizipationsphase aversiver Reize
(2024)
In dieser Arbeit wurden einerseits die Antizipationsphasen von aversiven gegenüber neutralen Reizen anhand von Messungen der Hautleitfähigkeit und der Startle-Reaktion untersucht. Andererseits wurde die Hautleitfähigkeit auch während der Präsentation aversiver und neutraler Reize mit dem Ziel gemessen, signifikante Unterschiede festzustellen. Insbesondere wurden die Auswirkungen der Allele der Gene ASIC1 und der Interaktion der Genallele BDNF und NPSR1 betrachtet.
Ziel der vorliegenden Arbeit war es, den Einfluss der Risikogene auf die physiologische Angstreaktion und die subjektive Angstwahrnehmung zu untersuchen. Hierzu wurden den genotypisierten Probanden aversive und neutrale Videos präsentiert. Vor jedem Video erfolgte die Ankündigung, ob es sich um ein neutrales oder aversives Video handelt, wodurch bei Letzterem im Allgemeinen antizipatorische Angst – Erwartungsangst – hervorgerufen wird.
Im Vergleich der Antizipationsphase vor Darbietung aversiver Videos mit der Antizipationsphase vor neutralen Videos konnte eine erhöhte Startle-Amplitude gemessen werden. Jedoch konnte weder anhand der Veränderung der Hautleitfähigkeit noch anhand der Startle-Amplitude ein signifikanter Unterschied bei Trägern und Nicht- Trägern der Risikogenallelen in der Antizipationsphase festgestellt werden. Während der Präsentation der Videos konnte für die aversiven Videos im Vergleich zu den neutralen eine erhöhte Hautleitfähigkeit gemessen werden. Ebenfalls konnte bei der Darbietung von aversiven Videos bei den Trägern der Genallel-Interaktion NPSR1 AT/TT * BDNF GG und den Trägern des Risikogenallels ASIC1TT eine erhöhte Hautleitfähigkeit gemessen werden. So konnte mit den Ergebnissen dieser Arbeit belegt werden, dass Antizipationsangst auslösbar und anhand der Startle-Amplitude messbar ist.
Um Antizipationsangst festzustellen oder diese bei Risikogenallel-Träger zu untersuchen, waren die Ergebnisse bezüglich der Hautleitfähigkeit jedoch weniger aussagekräftig als erwartet.
Allgemein konnte die Interaktion NPSR1 AT/TT * BDNF GG und ASIC1 TT als Risikogenallele bezüglich einer verstärken Reaktion auf aversive Reize bestätigt werden. Weitere Studien sind notwendig, um die genetische Komponente von Angst und damit auch von Angsterkrankungen näher zu beleuchten, damit zukünftige Diagnostik- und Therapieansätze präzise entwickelt werden können.
Background
With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far, volumetric brain changes have been proposed as clinical endpoints in the literature, but cognitive scores are still lacking. This study followed disease progression predominantly in language-based performance within 1 year and defined a PPA sum score which can be used in therapeutic interventions.
Methods
We assessed 28 patients with nonfluent variant PPA, 17 with semantic variant PPA, 13 with logopenic variant PPA, and 28 healthy controls in detail for 1 year. The most informative neuropsychological assessments were combined to a sum score, and associations between brain atrophy were investigated followed by a sample size calculation for clinical trials.
Results
Significant absolute changes up to 20% in cognitive tests were found after 1 year. Semantic and phonemic word fluency, Boston Naming Test, Digit Span, Token Test, AAT Written language, and Cookie Test were identified as the best markers for disease progression. These tasks provide the basis of a new PPA sum score. Assuming a therapeutic effect of 50% reduction in cognitive decline for sample size calculations, a number of 56 cases is needed to find a significant treatment effect. Correlations between cognitive decline and atrophy showed a correlation up to r = 0.7 between the sum score and frontal structures, namely the superior and inferior frontal gyrus, as well as with left-sided subcortical structures.
Conclusion
Our findings support the high performance of the proposed sum score in the follow-up of PPA and recommend it as an outcome measure in intervention studies.
Background
Disentangling the etiology of common, complex diseases is a major challenge in genetic research. For bipolar disorder (BD), several genome-wide association studies (GWAS) have been performed. Similar to other complex disorders, major breakthroughs in explaining the high heritability of BD through GWAS have remained elusive. To overcome this dilemma, genetic research into BD, has embraced a variety of strategies such as the formation of large consortia to increase sample size and sequencing approaches. Here we advocate a complementary approach making use of already existing GWAS data: a novel data mining procedure to identify yet undetected genotype–phenotype relationships. We adapted association rule mining, a data mining technique traditionally used in retail market research, to identify frequent and characteristic genotype patterns showing strong associations to phenotype clusters. We applied this strategy to three independent GWAS datasets from 2835 phenotypically characterized patients with BD. In a discovery step, 20,882 candidate association rules were extracted.
Results
Two of these rules—one associated with eating disorder and the other with anxiety—remained significant in an independent dataset after robust correction for multiple testing. Both showed considerable effect sizes (odds ratio ~ 3.4 and 3.0, respectively) and support previously reported molecular biological findings.
Conclusion
Our approach detected novel specific genotype–phenotype relationships in BD that were missed by standard analyses like GWAS. While we developed and applied our method within the context of BD gene discovery, it may facilitate identifying highly specific genotype–phenotype relationships in subsets of genome-wide data sets of other complex phenotype with similar epidemiological properties and challenges to gene discovery efforts.
Background
Temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS) is a common pharmaco-resistant epilepsy referred for adult epilepsy surgery. Though associated with prolonged febrile seizures (FS) in childhood, the neurobiological basis for this relationship is not fully understood and currently no preventive or curative therapies are available. DNA methylation, an epigenetic mechanism catalyzed by DNA methyltransferases (DNMTs), potentially plays a pivotal role in epileptogenesis associated with FS. In an attempt to start exploring this notion, the present cross-sectional pilot study investigated whether global DNA methylation levels (5-mC and 5-hmC markers) and DNMT isoforms (DNMT1, DNMT3a1, and DNMT3a2) expression would be different in hippocampal and neocortical tissues between controls and TLE patients with or without a history of FS.
Results
We found that global DNA methylation levels and DNMT3a2 isoform expression were lower in the hippocampus for all TLE groups when compared to control patients, with a more significant decrease amongst the TLE groups with a history of FS. Interestingly, we showed that DNMT3a1 expression was severely diminished in the hippocampus of TLE patients with a history of FS in comparison with control and other TLE groups. In the neocortex, we found a higher expression of DNMT1 and DNMT3a1 as well as increased levels of global DNA methylation for all TLE patients compared to controls.
Conclusion
Together, the findings of this descriptive cross-sectional pilot study demonstrated brain region-specific changes in DNMT1 and DNMT3a isoform expression as well as global DNA methylation levels in human TLE with or without a history of FS. They highlighted a specific implication of DNMT3a isoforms in TLE after FS. Therefore, longitudinal studies that aim at targeting DNMT3a isoforms to evaluate the potential causal relationship between FS and TLE or treatment of FS-induced epileptogenesis seem warranted.
Valence framing effects refer to inconsistent choice preferences in response to positive versus negative formulation of mathematically equivalent outcomes. Here, we manipulate valence framing in a two-alternative forced choice dictator game using gains and losses as frames to investigate the cognitive mechanisms underlying valence framing. We applied a Drift-Diffusion Model (DDM) to examine whether gain (i.e., “take” money) and loss (i.e., “give” money) frames evoke a cognitive bias as previous research did not consistently reveal framing effects using reaction times and response frequency as dependent variables. DDMs allow decomposing the decision process into separate cognitive mechanisms, whereby a cognitive bias was repeatedly associated with a shift in the starting point of the model. Conducting both a laboratory (N = 62) and an online study (N = 109), female participants allocated money between themselves and another person in a prosocial or selfish way. In each study, one group was instructed to give money (give frame), the other to take money (take frame). Consistent with previous studies, no differences were found in response times and response frequencies. However, in both studies, substantial bias towards the selfish option was found in the take frame groups, captured by the starting point of the DDM. Thus, our results suggest that valence framing induces a cognitive bias in decision processing in women, even when no behavioral differences are present.
Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose–concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20–60 ng/ml) is applicable for minors. In the 64 patients (aged 11–18 years) included, a positive correlation between daily dose and the active moiety (RIS\(_{am}\)) concentration was found (r\(_s\) = 0.49, p = 0.001) with variation in dose explaining 24% (r\(_s\)\(^2\) = 0.240) of the variability in serum concentrations. While the RIS\(_{am}\) concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RIS\(_{am}\) concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RIS\(_{am}\) was determined to be 33 ng/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions.
Schwangerschaft und Stillzeit gehen mit erheblichen metabolischen Veränderungen des mütterlichen Organismus einher. Bis dato ist über die Pharmakokinetik von Psychopharmaka in dieser Zeit wenig bekannt. In unserer naturalistischen Beobachtungsstudie untersuchten wir 61 Frauen hinsichtlich der Dynamik psychotroper Medikamente innerhalb der Schwangerschaft und Stillzeit im Serum und teils in der Muttermilch. Zudem erhoben wir Eckdaten der Entwicklung der exponierten Kinder innerhalb des ersten Lebensjahres.
Bis auf Citalopram stellten wir bei allen analysierten Medikamenten Spiegelabfälle in der Schwangerschaft fest: vom ersten zum zweiten Trimenon fielen die Spiegel bei Escitalopram, Sertralin, Duloxetin, Amitriptylin, Clomipramin und Quetiapin. Während wir in der Spätschwangerschaft bei Escitalopram, Venlafaxin, Clomipramin, Mirtazapin, Aripiprazol und Quetiapin eine weitere Reduktion der Serumkonzentrationen protokollierten, blieben die Spiegel von Amitriptylin stabil, die Sertralin-Spiegel erholten sich sogar partiell. Citalopram zeigte keine Änderung der Serumspiegel. Direkt postpartal kam es bei allen Medikamenten zu einem Spiegelanstieg. Im postpartalen Verlauf zeigten die einzelnen Medikamente widersprüchliche Dynamiken. Hohe Penetrationsraten in die Muttermilch wiesen Escitalopram und Venlafaxin auf; Duloxetin, Clomipramin und Quetiapin gingen kaum bzw. nicht in die Muttermilch über. Wir fanden keine signifikanten Unterschiede zwischen in utero nicht exponierten zu exponierten Kindern bezüglich Geburtsparametern wie Schwangerschaftswoche, Körpermaße oder APGAR-Wert. Während die nicht exponierten Kinder vermehrt unter leichten Auffälligkeiten direkt postpartal litten, wiesen die exponierten Neugeborenen mehr mittelschwere Auffälligkeiten auf. Hinsichtlich der Entwicklung innerhalb des ersten Lebensjahres (gemessen an groben Entwicklungsmeilensteinen) ergaben sich keine signifikanten Unterschiede.
Im klinischen Alltag trägt das Therapeutische Drug Monitoring als indirekte Methode zur Kontrolle aller an der Metabolisierung beteiligten Faktoren enorm zur Steigerung der Sicherheit und Effektivität der individuellen Pharmakotherapie bei. Die pharmakokinetische Dynamik fällt bei manchen Medikamenten jedoch interindividuell sehr unterschiedlich aus (insbesondere bei Sertralin); hier stellt eine initiale Genotypisierung der Cytochrom-P450-Enzyme ein großes Potential dar, um bereits zu Beginn einer Schwangerschaft über die voraussichtliche pharmakokinetische Dynamik im Bilde zu sein und möglicher Unter- bzw. Überdosierung mit potentiell fruchtschädigender Wirkung vorbeugen zu können.
Die ängstliche Depression stellt einen Subtypus der Depression dar, der noch nicht ausreichend erforscht ist und somit eine Herausforderung im klinischen Alltag darstellt. Laut der bisherigen Literatur sind genetische Unterschiede sowie Kindheitstraumatisierungen an der Pathophysiologie von Depressionen beteiligt und mitverantwortlich für die Ausprägung des Subtypus ängstliche Depression.
In dieser Untersuchung wurde erforscht, ob es unterschiedliche Genexpressionslevel des Gens NR3C1 zwischen ängstlich-depressiven und nicht-ängstlich-depressiven Personen gibt. Zusätzlich wurde geprüft, ob Kindheitstraumatisierungen einen weiteren Einfluss auf die Genexpression der beiden Subtypen der Depression haben.
Es zeigte sich, dass ängstlich-depressive Personen in Woche 1 bis 4 höhere HAM-D-Summenwerte erzielten, mit zusätzlichen Kindheitstraumatisierungen wurden die höchsten HAM-D-Werte festgestellt. Diese Gruppe hatte gehäuft Kindheitstraumata im Fragebogen angegeben, die Traumata Emotionale Misshandlung und Körperliche Vernachlässigung kamen signifikant häufiger vor.
Anhand dieser durchgeführten Studie konnten zusammengefasst werden, dass sich die Genexpressionslevel von NR3C1 zwischen den beiden Subtypen als unterschiedlich erwies. Zusätzlich scheinen die beiden Kindheitstraumata Emotionale Misshandlung und Körperliche Vernachlässigung einen weiteren Einfluss auf die Genexpression von NR3C1 zu haben.
Die unterschiedliche Genexpression von NR3C1 deutet auf verschiedene Funktionsweisen des GR zwischen den Subtypen hin. Dies könnte für die Verlaufsbeurteilung und Therapieansätze der Erkrankung von Bedeutung sein. Die häufiger vorkommenden Kindheitstraumatisierungen bei ängstlich-depressiven Personen können als ein pathophysiologischer Baustein für die Entstehung der ängstlichen Depression gesehen werden. Daher ist es umso wichtiger, das Überprüfen von erlebten Kindheitstraumata bei initialer Befragung in den klinischen Alltag mitaufzunehmen. Da auch der Depressionsschweregrad durch Kindheitstraumatisierungen in dieser Studie zunahm, ergeben sich daraus mögliche Konsequenzen für die therapeutische Planung.
Neural responses to a working memory task in acute depressed and remitted phases in bipolar patients
(2023)
(1) Cognitive impairments such as working memory (WM) deficits are amongst the most common dysfunctions characterizing bipolar disorder (BD) patients, severely contributing to functional impairment. We aimed to investigate WM performance and associated brain activation during the acute phase of BD and to observe changes in the same patients during remission. (2) Frontal brain activation was recorded using functional near-infrared spectroscopy (fNIRS) during n-back task conditions (one-back, two-back and three-back) in BD patients in their acute depressive (n = 32) and remitted (n = 15) phases as well as in healthy controls (n = 30). (3) Comparison of BD patients during their acute phase with controls showed a trend (p = 0.08) towards lower dorsolateral prefrontal cortex (dlPFC) activation. In the remitted phase, BD patients showed lower dlPFC and ventrolateral prefrontal cortex (vlPFC) activation (p = 0.02) compared to controls. No difference in dlPFC and vlPFC activation between BD patients’ phases was found. (4) Our results showed decreased working memory performance in BD patients during the working memory task in the acute phase of disease. Working memory performance improved in the remitted phase of the disease but was still particularly attenuated for the more demanding conditions.
Aggression and deficient cognitive control problems are widespread in psychiatric disorders, including major depressive disorder (MDD). These abnormalities are known to contribute significantly to the accompanying functional impairment and the global burden of disease. Progress in the development of targeted treatments of excessive aggression and accompanying symptoms has been limited, and there exists a major unmet need to develop more efficacious treatments for depressed patients. Due to the complex nature and the clinical heterogeneity of MDD and the lack of precise knowledge regarding its pathophysiology, effective management is challenging. Nonetheless, the aetiology and pathophysiology of MDD has been the subject of extensive research and there is a vast body of the latest literature that points to new mechanisms for this disorder. Here, we overview the key mechanisms, which include neuroinflammation, oxidative stress, insulin receptor signalling and abnormal myelination. We discuss the hypotheses that have been proposed to unify these processes, as many of these pathways are integrated for the neurobiology of MDD. We also describe the current translational approaches in modelling depression, including the recent advances in stress models of MDD, and emerging novel therapies, including novel approaches to management of excessive aggression, such as anti-diabetic drugs, antioxidant treatment and herbal compositions.
Ziel dieser Arbeit war es, den Einfluss psychosozialer Belastungsfaktoren auf den Verlauf einer Stammzelltransplantation zu untersuchen. Die primäre Fragestellung war, ob sich das Vorliegen einer posttraumatischen Belastungsstörung (PTSD) auf die Dauer der Immunrekonstitution, gemessen an der Aplasiezeit, auswirkt. Der Untersuchung liegen Daten aus der Medizinischen Klinik und Poliklinik II des Universitätsklinikums Würzburg zugrunde, die im Rahmen einer monozentrischen Querschnittsstudie erhoben wurden. An der Studie nahmen 50 Patienten mit der Diagnose eines Multiplen Myeloms teil, die am Tag ihrer ersten autologen Stammzelltransplantation befragt wurden. Anhand von Fragebögen konnten die Patienten Angaben zu ihrer individuellen psychischen Belastung machen. Für die statistische Auswertung wurden die Angaben aus dem NCCN-Distress-Thermometer und dem PCL-C ausgewertet.
Neuromelanin granules (NMGs) are organelle-like structures present in the human substantia nigra pars compacta. In addition to neuromelanin, NMGs contain proteins, lipids and metals. As NMG-containing dopaminergic neurons are preferentially lost in Parkinson’s disease and dementia with Lewy bodies (DLB), it is assumed that NMGs may play a role in neurodegenerative processes. Until now, this role is not completely understood and needs further investigation. We therefore set up an exploratory proteomic study to identify differences in the proteomic profile of NMGs from DLB patients (n = 5) compared to healthy controls (CTRL, n = 5). We applied a laser microdissection and mass-spectrometry-based approach, in which we used targeted mass spectrometric experiments for validation. In NMG-surrounding (SN\(_{Surr.}\)) tissue of DLB patients, we found evidence for ongoing oxidative damage and an impairment of protein degradation. As a potentially disease-related mechanism, we found α-synuclein and protein S100A9 to be enriched in NMGs of DLB cases, while the abundance of several ribosomal proteins was significantly decreased. As S100A9 is known to be able to enhance the formation of toxic α-synuclein fibrils, this finding points towards an involvement of NMGs in pathogenesis, however the exact role of NMGs as either neuroprotective or neurotoxic needs to be further investigated. Nevertheless, our study provides evidence for an impairment of protein degradation, ongoing oxidative damage and accumulation of potentially neurotoxic protein aggregates to be central mechanisms of neurodegeneration in DLB.
Decreased oligodendrocyte number in hippocampal subfield CA4 in schizophrenia: a replication study
(2022)
Hippocampus-related cognitive deficits in working and verbal memory are frequent in schizophrenia, and hippocampal volume loss, particularly in the cornu ammonis (CA) subregions, was shown by magnetic resonance imaging studies. However, the underlying cellular alterations remain elusive. By using unbiased design-based stereology, we reported a reduction in oligodendrocyte number in CA4 in schizophrenia and of granular neurons in the dentate gyrus (DG). Here, we aimed to replicate these findings in an independent sample. We used a stereological approach to investigate the numbers and densities of neurons, oligodendrocytes, and astrocytes in CA4 and of granular neurons in the DG of left and right hemispheres in 11 brains from men with schizophrenia and 11 brains from age- and sex-matched healthy controls. In schizophrenia, a decreased number and density of oligodendrocytes was detected in the left and right CA4, whereas mean volumes of CA4 and the DG and the numbers and density of neurons, astrocytes, and granular neurons were not different in patients and controls, even after adjustment of variables because of positive correlations with postmortem interval and age. Our results replicate the previously described decrease in oligodendrocytes bilaterally in CA4 in schizophrenia and point to a deficit in oligodendrocyte maturation or a loss of mature oligodendrocytes. These changes result in impaired myelination and neuronal decoupling, both of which are linked to altered functional connectivity and subsequent cognitive dysfunction in schizophrenia.
Even though exposure-based cognitive behavioral therapy (CBT) constitutes a first-line treatment for anxiety disorders, a substantial proportion of patients does not respond in a clinically significant manner. The identification of pre-treatment patient characteristics that are associated with treatment outcome might aid in improving response rates. Therefore, the present doctoral thesis aimed at investigating moderators of treatment outcome in anxiety disorders: first, we investigated the neural correlates of comorbidity among primary panic disorder/agoraphobia (PD/AG) and secondary social anxiety disorder (SAD) moderating treatment outcome towards exposure-based CBT. Second, pre-treatment functional resting-state connectivity signatures of treatment response in specific phobia were studied. Within the first study, we compared PD/AG patients with or without secondary SAD regarding their clinical and neurofunctional outcome towards a manualized CBT treatment focusing on PD/AG symptoms. Prior to treatment, PD/AG+SAD compared to PD/AG-SAD patients exhibited a specific neural signature within the temporal lobe, which was attenuated to the level of PD/AG-SAD patients afterwards. CBT was equally effective in both groups. Thus, comorbidity among those two anxiety disorders did not alter treatment outcome substantially. This might be due to the high overlap of shared pathophysiological features within both disorders. In the second study, we assessed pre-treatment functional resting-state connectivity within a sample of spider phobic patients that were treated with massed in virtuo exposure. We found responders already prior to treatment to be characterized by stronger inhibitory frontolimbic connectivity as well as heightened connectivity between the amygdala and regions related to the ventral visual stream. Furthermore, patients demonstrating high within-session extinction exhibited pronounced intrinsic prefrontal connectivity. Our results point to responders exhibiting a brain prepared for the mechanism of action of exposure. Taken together, results highlight the major impact of pre-treatment characteristics on treatment outcome. Both, PD/AG+SAD patients as well as responders within the SpiderVR study exhibited heightened activation or connectivity within the ventral visual pathway and the amygdala. Pronounced visual processing together with enhanced executive control and emotion regulation seem to constitute a fruitful soil for successful exposure. The results provide starting points for personalized treatment approaches in order to improve treatment success in the anxiety disorders. Future studies are needed to investigate the benefit of neuroscientifically informed CBT augmentation strategies such as repetitive transcranial magnetic stimulation.
While the healthy brain works through balanced synaptic communication between
glutamatergic and GABAergic neurons to coordinate excitation (E) and inhibition (I), disruption
of E/I balance interferes with synaptic communication, information processing, and ultimately
cognition. Multiple line of evidence indicates that E/I imbalance represents the
pathophysiological basis of a wide spectrum of mental disorders. Genetic screening
approaches have identified Cadherin-13 (CDH13). as a risk gene across neurodevelopmental
and mental disorders. CDH13 regulates several cellular and synaptic processes in brain
development and neuronal plasticity in adulthood. In addition to other functions, it is specifically
localized at inhibitory synapses of parvalbumin- and somatostatin-expressing GABAergic
neurons. In support of CDH13’s function in moderating E/I balance, electrophysiological
recordings of hippocampal slices in a CDH13-deficient mouse model revealed an increase in
basal inhibitory but not excitatory synaptic transmission. Moreover, the search for genetic
variants impacting functional expression of the CDH13 gene identified SNP (single nucleotide
polymorphism)) rs2199430 in intron 1 to be associated with differential mRNA concentrations
in human post-mortem brain across the three genotypes CDH13G/G, CDH13A/G and CDH13A/A
.
This work therefore aimed to further validate these findings in a complementary human model
by using induced pluripotent stem cells (iPSCs). The application of human iPSCs in research
has replaced the use of embryonic cells, resolving the ethical conflict of destructive usage of
human embryos. Investigating CDH13’s mode of action in inhibitory synapses was predicted
to facilitate mechanistic insight into the effects of CDH13 gene variants on E/I network activity,
which can then be targeted to reinstate balance.
Genome-wide association studies have identified rare copy number variants (CNVs) resulting
in a deletion (or duplication) of CDH13. To reduce genetic background variance, a set of
isogenic iPSC lines with a gene dose-dependent deficiency of CDH13 (CDH13-/- and CDH13+/-
) was generated by using the Clustered Regulatory Interspaced Short Palindromic
Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system. These CRISPRed iPSCs
carrying a single or two allele(s) with CDH13 inactivation facilitate investigation of CDH13
function in cellular processes, at inhibitory synapses and in neuronal network activity. In
addition, iPSCs carrying allelic SNP rs2199430 variants were used to study the effects of
common genetic variation of CDH13. These cell lines were differentiated into pure
glutamatergic and GABAergic neurons and co-cultured to generate neuronal networks allowing
its activity to be measured and correlated with electrophysiological signatures of differential
CDH13 genotypes. The work towards assessment of neuronal network activity of the iPSC
lines was subdivided into three major steps: first, generating rtTA/Ngn2 and rtTA/Ascl1-positive
iPSCs via a lentivirus-mediated approach; second, differentiating pure glutamatergic and
GABAergic neurons from the genetically transduced iPSCs and co-culturing of pure
glutamatergic and GABAergic neurons in a pre-established ratio (65:35) by direct
differentiation upon supplementation with doxycycline and forskolin on a microelectrode array
(MEA) chip; and, finally, recording of neuronal network activity of iPSC lines after 49 days in
vitro, followed by extraction and analyses of multiple MEA parameters.
x
Based on the MEA parameters, it was confirmed that complete CDH13 knockout as well as
heterozygous deficiency influence E/I balance by increasing inhibition. It was further revealed
that common SNP variation alters the signature of neuronal network activity. Specifically,
CDH13 deficiency resulted in a significant reduction in network burst duration (NBD), reduced
number of detected spikes within a network burst and reduction in network burst rate (NBR)
compared to the control (CDH13G/G). CDH13A/G and CDH13A/A showed similarities with the
CRISPRed CDH13-deficient networks by showing a significant reduction in the NBD and a
reduced number of detected spikes within a network compared to CDH13G/G. Strikingly. there
was a significant increase in the NBR of the CDH13A/G and CDH13A/A compared to CDH13G/G
networks. CDH13A/G networks exhibited significant differences in both parameters. At the
cellular level, this indicates that signalling pathways which determine the length and frequency
of network bursts differ among allelic variants of SNP rs2199430, thus confirming functional
relevance of this intronic SNP.
In summary, CDH13-deficient isogenic iPSC lines were generated using CRISPR/Cas9, iPSCs
were genetically transduced via a lentivirus approach, direct differentiation of
glutamatergic/GABAergic neurons derived from transduced iPSCs were used to establish a
scalable co-culture system, and network activity was recorded by MEA using pre-established
parameters to extract and analyze activity information. The results indicate that iPSC-derived
neuronal networks following CRISPR/Cas9-facilitated CDH13 inactivation, as well as networks
with allelic SNP variants of CDH13, moderate E/I balance, thus advancing understanding of
CDH13 function at inhibitory synapses and elucidating the effects of rare and common CDH13
gene variation.
Predictability of threat is one of the key modulators of neural activity in fear and anxiety-related threat processes and there is a considerable number of studies focusing on the exact contribution of centromedial amygdala and Bed nucleus of stria terminalis (BNST) in animals as well as in humans. In this research field, some studies already investigated the differential involvement of both areas during temporally predictable and unpredictable threat processes in humans. However, these studies showed several limitations e.g. small sample size, no predictable threat conditions, no separation of anticipation and confrontation processes, which should be addressed in future studies. Furthermore, evidence for group-based inter-individual differences of amygdala and BNST activity during predictable and unpredictable threat processes have not been studied extensively.
Several studies suggest a relevant role of the amygdala and BNST activity in phobic processes in patients with specific phobia, but no study so far has investigated the exact contribution of centromedial amygdala (CM) and BNST during temporally predictable and unpredictable threat processes in specific phobia.
This thesis consisted of three studies and aimed to evaluate the exact contribution of CM and BNST during temporally predictable and unpredictable threat anticipation and confrontation with the use of an optimized functional magnetic resonance imaging (fMRI) paradigm, which aimed to solve methodological limitations of recent studies. Study 1 used a large sample of healthy participants who were grouped based on NPSR1 genotype, and study 2 and study 3 used a sample of patients with spider phobia. In sum, the results of all three studies indicated, that BNST is more relevant for anticipation processes as compared to the CM. Contrary, during the confrontation phase the CM displays a greater relevance for threat confrontation processes.
In recent years, various studies have investigated the extent to which treatment success can be predicted in patients with anxiety disorders based on pre-treatment fMRI activity. Therefore, this was investigated for the first time in study 3 in patients with spider phobia during temporally predictable and unpredictable threat processes. Results indicated that independent of temporal predictability lower anterior cingulate cortex (ACC) activity during threat anticipation and engaged BNST during threat confrontation might be benefitting factors for successful therapy response in spider phobia.
Dementia, including Alzheimer's disease, is a growing problem worldwide. Prevention or early detection of the disease or a prodromal cognitive decline is necessary. By means of our long-term follow-up ‘Vogel study’, we aim to predict the pathological cognitive decline of a German cohort (mean age was 73.9 ± 1.55 years at first visit) with three measurement time points within 6 years per participant. Especially in samples of the elderly and subjects with chronic or co-morbid diseases, dropouts are one of the biggest problems of long-term studies. In contrast to the large number of research articles conducted on the course of dementia, little research has been done on the completion of treatment. To ensure unbiased and reliable predictors of cognitive decline from study completers, our objective was to determine predictors of dropout. We conducted multivariate analyses of covariance and multinomial logistic regression analyses to compare and predict the subject's dropout behaviour at the second visit 3 years after baseline (full participation, partial participation and no participation/dropout) with neuropsychiatric, cognitive, blood and lifestyle variables. Lower performance in declarative memory, attention and visual–spatial processing predicted dropout rather than full participation. Lower performance in visual–spatial processing predicted partial participation as opposed to full participation. Furthermore, lower performance in mini-mental status examination predicted whether subjects dropped out or participated partially instead of full participation. Baseline cognitive parameters are associated with dropouts at follow-up with a loss of impaired participants. We expect a bias into a healthier sample over time.
Objective
Alzheimer’s disease (AD) is a growing challenge worldwide, which is why the search for early-onset predictors must be focused as soon as possible. Longitudinal studies that investigate courses of neuropsychological and other variables screen for such predictors correlated to mild cognitive impairment (MCI). However, one often neglected issue in analyses of such studies is measurement invariance (MI), which is often assumed but not tested for. This study uses the absence of MI (non-MI) and latent factor scores instead of composite variables to assess properties of cognitive domains, compensation mechanisms, and their predictability to establish a method for a more comprehensive understanding of pathological cognitive decline.
Methods
An exploratory factor analysis (EFA) and a set of increasingly restricted confirmatory factor analyses (CFAs) were conducted to find latent factors, compared them with the composite approach, and to test for longitudinal (partial-)MI in a neuropsychiatric test battery, consisting of 14 test variables. A total of 330 elderly (mean age: 73.78 ± 1.52 years at baseline) were analyzed two times (3 years apart).
Results
EFA revealed a four-factor model representing declarative memory, attention, working memory, and visual–spatial processing. Based on CFA, an accurate model was estimated across both measurement timepoints. Partial non-MI was found for parameters such as loadings, test- and latent factor intercepts as well as latent factor variances. The latent factor approach was preferable to the composite approach.
Conclusion
The overall assessment of non-MI latent factors may pose a possible target for this field of research. Hence, the non-MI of variances indicated variables that are especially suited for the prediction of pathological cognitive decline, while non-MI of intercepts indicated general aging-related decline. As a result, the sole assessment of MI may help distinguish pathological from normative aging processes and additionally may reveal compensatory neuropsychological mechanisms.
There is still limited knowledge about alterations of blood concentrations of psychotropic drugs during pregnancy, the transfer of psychotropic drugs into breastmilk and the effects on exposed children. We investigated changes in concentrations of psychopharmacological medication during pregnancy and lactation in serum and breastmilk at different time points in a naturalistic sample of 60 mothers and observed the development of the exposed children in the first 12 months. We found a decrease in serum concentrations from the first to the second trimester of amitriptyline, duloxetine, escitalopram, quetiapine and sertraline. Citalopram stayed rather stable during pregnancy, sertraline levels interestingly increased again from the second to the third trimester. High concentration-by-dose ratios in breastmilk were found for venlafaxine as well as lamotrigine, low for quetiapine and clomipramine. Similarly, clomipramine and quetiapine showed low milk/serum–penetration ratios. Regarding the birth outcome measures in children, we found no significant differences between in utero exposed compared to nonexposed newborns. There were no significant differences in the development in the first 12 months. Psychotropic medication in the peripartum needs a balancing of risks and benefits and a continuous therapeutic drug monitoring can be a guidance for clinicians to monitor drug alteration patterns, which are likely to occur due to physiological pregnancy-associated changes in pharmacokinetics. Accordingly, therapeutic drug monitoring can optimize a medication in pregnancy and lactation with the lowest effective dose.
Die vorliegende retrospektive Untersuchung arbeitete mit Daten von 153 Patienten der Neurogerontopsychiatrischen Tagesklinik Würzburg. Dabei wurde zum einen geprüft, ob multimorbide Patienten und niereninsuffiziente Patienten höhere dosiskorrigierte Serumkonzentrationen der Antidepressiva Escitalopram, Sertralin, Venlafaxin und Mirtazapin aufwiesen. Zum anderen erfolgte die Untersuchung, ob hohe Serumkonzentrationen der vier
genannten Antidepressiva zu einem besseren Therapieergebnis führten.
Für die Berechnungen wurden die letzten vor Entlassung erhobenen Laborparameter verwendet. Es erfolgte die Berechnung der dosiskorrigierten Serumkonzentration. 76 Patienten (49,7 %) wurden als multimorbide eingestuft.
Es zeigten sich für die dosiskorrigierte Serumkonzentration des
aktiven Metaboliten O-Desmethyl-Venlafaxin statistisch signifikant höhere
Konzentrationen bei der multimorbiden Subgruppe.
Ferner zeigte sich bei 140 Patienten eine Niereninsuffizienz (91,5 %). Für die dosiskorrigierte Konzentration von O-Desmethyl Venlafaxin, die dosiskorrigierte Summenserumkonzentration aus Venlafaxin und O-Desmethyl- Venlafaxin sowie die dosiskorrigierte Serumkonzentration von Sertralin ließen sich statistisch signifikant höhere Konzentrationen bei einer zunehmenden Einschränkung der Nierenfunktion nachweisen.
Es zeigte sich kein Einfluss der Höhe der dosiskorrigierten Serumkonzentration der
Antidepressiva auf das Therapieergebnis in der vorliegenden Arbeit.
Mit der vorliegenden Arbeit konnte gezeigt werden, dass sowohl Multimorbidität als
auch Niereninsuffizienz einen Einfluss auf die Verstoffwechselung und
auch die dosiskorrigierte Serumkonzentration der Antidepressiva Venlafaxin und
Sertralin haben. Daher ergibt sich die Schlussfolgerung, dass bei
älteren Patienten, welche von Multimorbidität oder Niereninsuffizienz betroffen sind,
eine Dosisanpassung und regelmäßige Kontrollen der Serumkonzentration im Sinne
eines Therapeutischen Drug Monitoring erfolgen sollten.
Lithium salts are the first-line prophylaxis treatment for bipolar disorder in most guidelines. The majority of bipolar women are treated with mood stabilizers at the time they wish to get pregnant. One reason for this is the rising average age at first childbirth, at least in the high-income countries, which increases in general the likelihood of a medication with psychotropic drugs. Previously, lithium exposition during pregnancy was thought to strongly increase the risk of severe cardiac malformation. However, recent studies only point to a low teratogenic risk, so nowadays an increasing number of women are getting pregnant with ongoing lithium treatment. Regarding lithium medication during breastfeeding, there is evidence that lithium transfers to the breastmilk and can also be detected in the infants' serum. The influence on the infant is still a largely understudied topic. Regular monitoring of the infants' renal clearance, thyroid function, and lithium levels is warranted when breastfeeding under lithium exposure. In this case series, we present three case reports of bipolar mothers who were treated with lithium during pregnancy and breastfeeding to add to the scarce literature on this important topic. In short, we strengthen the importance of therapeutic drug monitoring due to fluctuating plasma levels during pregnancy and after birth, and we can report the birth and development of three healthy infants despite lithium medication during pregnancy and breastfeeding.
Bereits in vorausgegangenen Studien konnte nachgewiesen werden, dass das Stathmin-Gen eine entscheidende Rolle im Hinblick auf erlernte und angeborene Angstreaktionen spielt. So konnte Frau Dr. Julia Katharina Heupel in ihrer Arbeit aus dem Jahr 2013 eine Assoziation eines (TAA)n-Polymorphismus, welcher sich ca. 2 kb upstream des ersten Exons des Stathmin-Gens und ca. 4 kb upstream des Translationsstarts befindet, mit Cluster-C-Persönlichkeitsstörungen belegen.
Sie vermutete, dass eine Hochregulation der Expression des Stathmin-Gens ein Risikofaktor für die Entstehung von Cluster C Persönlichkeitsstörungen darstellen könnte.
Da sich der beschriebene Polymorphismus in der Promotor-Region des Stathmin-Gens befindet, ist eine allelspezifische Auswirkung auf die Genexpression vorstellbar. Um diese Vermutung zu stützen, wurde in dieser Arbeit die Auswirkung zweier Allele des STR-Polymorphismus im Bereich der Promotorregion des Stathmin-Gens im Hinblick auf die Promotoraktivität untersucht.
Hierzu wurde die zu untersuchende Sequenz zunächst mittels Polymerase-Ketten-Reaktion vervielfältigt und anschließend in einen pGL4.23.Vektor kloniert.
Im Anschluss daran erfolgte die Untersuchung der Promotoraktivität mittels eines Luciferase-Assays in der humanen Neuroblastomzelllinie SH-SY5Y.
Nach statischer Auswertung der Messreihen zeigte sich eine signifikant höhere Luciferase-Aktivität des STR-Polymorphismus (TAA)12 im Vergleich zu dem STR-Polymorphismus (TAA)13.
Hierdurch kann von einer höheren Promotoraktivität bei dem Genotyp (TAA)12 gegenüber dem Genotyp (TAA)13 ausgegangen werden.
Zusammenfassend unterstützen die Ergebnisse dieser Arbeit die These, dass es sich bei dem Stathmin-Gen um ein Suszeptibilitätsgen für die Entstehung von Cluster C Persönlichkeitsstörungen handeln könnte.
Social contact is an integral part of daily life. Its health-enhancing effects include reduced negative affective experiences of fear and anxiety, a phenomenon called social buffering. This dissertation studied different forms of social contact and their anxiety-buffering effects with diverse methodologies.
The laboratory-based first study investigated minimal social contact in the context of pain relief learning. Results showed that the observed decreased autonomic and increased subjective fear responses following pain relief learning were independent of social influence. The minimalistic and controlled social setting may have prevented social buffering. Study 2 targeted social buffering in daily life using Ecological Momentary Assessment. We repeatedly assessed individuals’ state anxiety, related cardiovascular responses, and aspects of social interactions with smartphones and portable sensors on five days. Analyses of over 1,500 social contacts revealed gender-specific effects, e.g., heart rate-reducing effects of familiarity in women, but not men. Study 3 examined anxiety, loneliness, and related social factors in the absence of social contact due to social distancing. We constructed and validated a scale measuring state and trait loneliness and isolation, and analysed its link to mental health. Results include a social buffering-like relation of lower anxiety with more trait sociability and sense of belonging.
In sum, the studies showed no fear reduction by minimal social contact, but buffering effects relating to social and personal factors in more complex social situations. Anxiety responses during daily social contacts were lower with more familiar or opposite-gender interaction partners. During limited social contact, lower anxiety related to inter-individual differences in sociability, social belonging, and loneliness. By taking research from lab to life, this dissertation underlined the diverse nature of social contact and its relevance to mental health.
The hippocampal formation is a brain structure integrally involved in episodic memory, spatial navigation, cognition and stress responsiveness. Structural abnormalities in hippocampal volume and shape are found in several common neuropsychiatric disorders. To identify the genetic underpinnings of hippocampal structure here we perform a genome-wide association study (GWAS) of 33,536 individuals and discover six independent loci significantly associated with hippocampal volume, four of them novel. Of the novel loci, three lie within genes (ASTN2, DPP4 and MAST4) and one is found 200 kb upstream of SHH. A hippocampal subfield analysis shows that a locus within the MSRB3 gene shows evidence of a localized effect along the dentate gyrus, subiculum, CA1 and fissure. Further, we show that genetic variants associated with decreased hippocampal volume are also associated with increased risk for Alzheimer’s disease (r\(_g\)=−0.155). Our findings suggest novel biological pathways through which human genetic variation influences hippocampal volume and risk for neuropsychiatric illness.
Background: There is increasing evidence for the role of prenatal stress in shaping offspring DNA methylation and disease susceptibility. In the current study, we aimed to identify genes and pathways associated with pregnancy anxiety using a genome-wide DNA methylation approach.
Methods: We selected 22 versus 23 newborns from our Prenatal Early Life Stress (PELS) cohort, exposed to the lowest or highest degree of maternal pregnancy anxiety, respectively. Cord blood genome-wide DNA methylation was assayed using the HumanMethylation450 BeadChip (HM450, n = 45) and candidate gene methylation using EpiTYPER (n = 80). Cortisol levels were measured at 2, 4, and 12 months of age to test infant stress system (re)activity.
Results: Data showed ten differentially methylated regions (DMR) when comparing newborns exposed to low versus high pregnancy anxiety scores. We validated a top DMR in the GABA-B receptor subunit 1 gene (GABBR1) revealing the association with pregnancy anxiety particularly in male newborns (most significant CpG Pearson R = 0.517, p = 0.002; average methylation Pearson R = 0.332, p = 0.039). Cord blood GABBR1 methylation was associated with infant cortisol levels in response to a routine vaccination at 4 months old.
Conclusions: In conclusion, our results show that pregnancy anxiety is associated with differential DNA methylation patterns in newborns and that our candidate gene GABBR1 is associated with infant hypothalamic-pituitary-adrenal axis response to a stressor. Our findings reveal a potential role for GABBR1 methylation in association with stress and provide grounds for further research.
Sustained anticipatory anxiety is central to Generalized Anxiety Disorder (GAD). During anticipatory anxiety, phasic threat responding appears to be mediated by the amygdala, while sustained threat responding seems related to the bed nucleus of the stria terminalis (BNST). Although sustained anticipatory anxiety in GAD patients was proposed to be associated with BNST activity alterations, firm evidence is lacking. We aimed to explore temporal characteristics of BNST and amygdala activity during threat anticipation in GAD patients. Nineteen GAD patients and nineteen healthy controls (HC) underwent functional magnetic resonance imaging (fMRI) during a temporally unpredictable threat anticipation paradigm. We defined phasic and a systematic variation of sustained response models for blood oxygen level-dependent responses during threat anticipation, to disentangle temporally dissociable involvement of the BNST and the amygdala. GAD patients relative to HC responded with increased phasic amygdala activity to onset of threat anticipation and with elevated sustained BNST activity that was delayed relative to the onset of threat anticipation. Both the amygdala and the BNST displayed altered responses during threat anticipation in GAD patients, albeit with different time courses. The results for the BNST activation hint towards its role in sustained threat responding, and contribute to a deeper understanding of pathological sustained anticipatory anxiety in GAD.
A systematic overview of mental and physical disorders of informal caregivers based on population-based studies with good methodological quality is lacking. Therefore, our aim was to systematically summarize mortality, incidence, and prevalence estimates of chronic diseases in informal caregivers compared to non-caregivers. Following PRISMA recommendations, we searched major healthcare databases (CINAHL, MEDLINE and Web of Science) systematically for relevant studies published in the last 10 years (without language restrictions) (PROSPERO registration number: CRD42020200314). We included only observational cross-sectional and cohort studies with low risk of bias (risk scores 0–2 out of max 8) that reported the prevalence, incidence, odds ratio (OR), hazard ratio (HR), mean- or sum-scores for health-related outcomes in informal caregivers and non-caregivers. For a thorough methodological quality assessment, we used a validated checklist. The synthesis of the results was conducted by grouping outcomes. We included 22 studies, which came predominately from the USA and Europe. Informal caregivers had a significantly lower mortality than non-caregivers. Regarding chronic morbidity outcomes, the results from a large longitudinal German health-insurance evaluation showed increased and statistically significant incidences of severe stress, adjustment disorders, depression, diseases of the spine and pain conditions among informal caregivers compared to non-caregivers. In cross-sectional evaluations, informal caregiving seemed to be associated with a higher occurrence of depression and of anxiety (ranging from 4 to 51% and 2 to 38%, respectively), pain, hypertension, diabetes and reduced quality of life. Results from our systematic review suggest that informal caregiving may be associated with several mental and physical disorders. However, these results need to be interpreted with caution, as the cross-sectional studies cannot determine temporal relationships. The lower mortality rates compared to non-caregivers may be due to a healthy-carer bias in longitudinal observational studies; however, these and other potential benefits of informal caregiving deserve further attention by researchers.
We performed a systematic search and meta-analysis of available literature to determine the safety profile of Cerebrolysin in acute ischemic stroke, filling existing safety information gaps and inconsistent results. We searched EMBASE, PubMed, and Cochrane Databases of Systematic Reviews and Clinical Trials up to the end of February 2021. Data collection and analysis were conducted using methods described in the Cochrane Handbook for Systematic Reviews of Interventions. All safety outcomes were analyzed based on risk ratios (RR) and their 95% confidence intervals. The meta-analysis pooled 2202 patients from twelve randomized clinical trials, registering non-statistically significant (p > 0.05) differences between Cerebrolysin and placebo throughout main and subgroup analyses. The lowest rate of Serious Adverse Events (SAE), as compared to placebo, was observed for the highest dose of Cerebrolysin (50 mL), highlighting a moderate reduction (RR = 0.6). We observed a tendency of superiority of Cerebrolysin regarding SAE in high dose treatment courses for moderate-severe ischemic stroke, suggesting some effect of the agent against adverse events. This comprehensive safety meta-analysis confirms the safety profile for patients treated with Cerebrolysin after acute ischemic stroke, as compared to placebo.
Background: The hypothalamus is an important brain region for the regulation of energy balance. Roux-en-Y gastric bypass (RYGB) surgery and gut hormone-based treatments are known to reduce body weight, but their effects on hypothalamic gene expression and signaling pathways are poorly studied. Methods: Diet-induced obese male Wistar rats were randomized into the following groups: RYGB, sham operation, sham + body weight-matched (BWM) to the RYGB group, osmotic minipump delivering PYY3-36 (0.1 mg/kg/day), liraglutide s.c. (0.4 mg/kg/day), PYY3-36 + liraglutide, and saline. All groups (except BWM) were kept on a free choice of high- and low-fat diets. Four weeks after interventions, hypothalami were collected for RNA sequencing. Results: While rats in the RYGB, BWM, and PYY3-36 + liraglutide groups had comparable reductions in body weight, only RYGB and BWM treatment had a major impact on hypothalamic gene expression. In these groups, hypothalamic leptin receptor expression as well as the JAK–STAT, PI3K-Akt, and AMPK signaling pathways were upregulated. No significant changes could be detected in PYY3-36 + liraglutide-, liraglutide-, and PYY-treated groups. Conclusions: Despite causing similar body weight changes compared to RYGB and BWM, PYY3-36 + liraglutide treatment does not impact hypothalamic gene expression. Whether this striking difference is favorable or unfavorable to metabolic health in the long term requires further investigation.
Attention-deficit hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder characterized by hyperactivity, impulsivity, and/or inattention, which are symptoms also observed in many rare genetic disorders. We searched for genes involved in Mendelian disorders presenting with ADHD symptoms in the Online Mendelian Inheritance in Man (OMIM) database, to curate a list of new candidate risk genes for ADHD. We explored the enrichment of functions and pathways in this gene list, and tested whether rare or common variants in these genes are associated with ADHD or with its comorbidities. We identified 139 genes, causal for 137 rare disorders, mainly related to neurodevelopmental and brain function. Most of these Mendelian disorders also present with other psychiatric traits that are often comorbid with ADHD. Using whole exome sequencing (WES) data from 668 ADHD cases, we found rare variants associated with the dimension of the severity of inattention symptoms in three genes: KIF11, WAC, and CRBN. Then, we focused on common variants and identified six genes associated with ADHD (in 19,099 cases and 34,194 controls): MANBA, UQCC2, HIVEP2, FOPX1, KANSL1, and AUH. Furthermore, HIVEP2, FOXP1, and KANSL1 were nominally associated with autism spectrum disorder (ASD) (18,382 cases and 27,969 controls), as well as HIVEP2 with anxiety (7016 cases and 14,475 controls), and FOXP1 with aggression (18,988 individuals), which is in line with the symptomatology of the rare disorders they are responsible for. In conclusion, inspecting Mendelian disorders and the genes responsible for them constitutes a valuable approach for identifying new risk genes and the mechanisms of complex disorders.
Antidepressants are used to treat several psychiatric disorders; however, a large proportion of patients do not respond to their first antidepressant therapy and often experience adverse drug reactions (ADR). A common insertion–deletion polymorphism in the promoter region (5-HTTLPR) of the serotonin transporter (SLC6A4) gene has been frequently investigated for its association with antidepressant outcomes. Here, we performed a systematic review and meta-analysis to assess 5-HTTLPR associations with antidepressants: (1) response in psychiatric disorders other than major depressive disorder (MDD) and (2) tolerability across all psychiatric disorders. Literature searches were performed up to January 2021, yielding 82 studies that met inclusion criteria, and 16 of these studies were included in the meta-analyses. Carriers of the 5-HTTLPR LL or LS genotypes were more likely to respond to antidepressant therapy, compared to the SS carriers in the total and European ancestry-only study populations. Long (L) allele carriers taking selective serotonin reuptake inhibitors (SSRIs) reported fewer ADRs relative to short/short (SS) carriers. European L carriers taking SSRIs had lower ADR rates than S carriers. These results suggest the 5-HTTLPR polymorphism may serve as a marker for antidepressant outcomes in psychiatric disorders and may be particularly relevant to SSRI treatment among individuals of European descent.
Genes encoding endocannabinoid and sphingolipid metabolism pathways were suggested to contribute to the genetic risk towards attention deficit hyperactivity disorder (ADHD). The present pilot study assessed plasma concentrations of candidate endocannabinoids, sphingolipids and ceramides in individuals with adult ADHD in comparison with healthy controls and patients with affective disorders. Targeted lipid analyses of 23 different lipid species were performed in 71 mental disorder patients and 98 healthy controls (HC). The patients were diagnosed with adult ADHD (n = 12), affective disorder (major depression, MD n = 16 or bipolar disorder, BD n = 6) or adult ADHD with comorbid affective disorders (n = 37). Canonical discriminant analysis and CHAID analyses were used to identify major components that predicted the diagnostic group. ADHD patients had increased plasma concentrations of sphingosine-1-phosphate (S1P d18:1) and sphinganine-1-phosphate (S1P d18:0). In addition, the endocannabinoids, anandamide (AEA) and arachidonoylglycerol were increased. MD/BD patients had increased long chain ceramides, most prominently Cer22:0, but low endocannabinoids in contrast to ADHD patients. Patients with ADHD and comorbid affective disorders displayed increased S1P d18:1 and increased Cer22:0, but the individual lipid levels were lower than in the non-comorbid disorders. Sphingolipid profiles differ between patients suffering from ADHD and affective disorders, with overlapping patterns in comorbid patients. The S1P d18:1 to Cer22:0 ratio may constitute a diagnostic or prognostic tool.
Occurrence of mental illness and mental health risks among the self-employed: a systematic review
(2021)
We aimed to systematically identify and evaluate all studies of good quality that compared the occurrence of mental disorders in the self-employed versus employees. Adhering to the Cochrane guidelines, we conducted a systematic review and searched three major medical databases (MEDLINE, Web of Science, Embase), complemented by hand search. We included 26 (three longitudinal and 23 cross-sectional) population-based studies of good quality (using a validated quality assessment tool), with data from 3,128,877 participants in total. The longest of these studies, a Swedish national register evaluation with 25 years follow-up, showed a higher incidence of mental illness among the self-employed compared to white-collar workers, but a lower incidence compared to blue-collar workers. In the second longitudinal study from Sweden the self-employed had a lower incidence of mental illness compared to both blue- and white-collar workers over 15 years, whereas the third longitudinal study (South Korea) did not find a difference regarding the incidence of depressive symptoms over 6 years. Results from the cross-sectional studies showed associations between self-employment and poor general mental health and stress, but were inconsistent regarding other mental outcomes. Most studies from South Korea found a higher prevalence of mental disorders among the self-employed compared to employees, whereas the results of cross-sectional studies from outside Asia were less consistent. In conclusion, we found evidence from population-based studies for a link between self-employment and increased risk of mental illness. Further longitudinal studies are needed examining the potential risk for the development of mental disorders in specific subtypes of the self-employed.
Objectives
The pathogenesis of fibromyalgia syndrome (FMS) is unclear. Transcranial ultrasonography revealed anechoic alteration of midbrain raphe in depression and anxiety disorders, suggesting affection of the central serotonergic system. Here, we assessed midbrain raphe echogenicity in FMS.
Methods
Sixty-six patients underwent transcranial sonography, of whom 53 were patients with FMS (27 women, 26 men), 13 patients with major depression and physical pain (all women), and 14 healthy controls (11 women, 3 men). Raphe echogenicity was graded visually as normal or hypoechogenic, and quantified by digitized image analysis, each by investigators blinded to the clinical diagnosis.
Results
Quantitative midbrain raphe echogenicity was lower in patients with FMS compared to healthy controls (p<0.05), but not different from that of patients with depression and accompanying physical pain. Pain and FMS symptom burden did not correlate with midbrain raphe echogenicity as well as the presence and severity of depressive symptoms.
Conclusion
We found reduced echogenicity of the midbrain raphe area in patients with FMS and in patients with depression and physical pain, independent of the presence or severity of pain, FMS, and depressive symptoms. Further exploration of this sonographic finding is necessary before this objective technique may enter diagnostic algorithms in FMS and depression.
This study examined (1) the availability and content of national CPGs for treatment of peripartum depression, including comorbid anxiety, with antidepressants and other psychotropics across Europe and (2) antidepressant and other psychotropic utilization data as an indicator of prescribers' compliance to the guidelines. We conducted a search using Medline and the Guidelines International Network database, combined with direct e-mail contact with national Riseup-PPD COST ACTION members and researchers within psychiatry. Of the 48 European countries examined, we screened 41 records and included 14 of them for full-text evaluation. After exclusion of ineligible and duplicate records, we included 12 CPGs. Multiple CPGs recommend antidepressant initiation or continuation based on maternal disease severity, non-response to first-line non-pharmacological interventions, and after risk-benefit assessment. Advice on treatment of comorbid anxiety is largely missing or unspecific. Antidepressant dispensing data suggest general prescribers' compliance with the preferred substances of the CPG, although country-specific differences were noted. To conclude, there is an urgent need for harmonized, up-to-date CPGs for pharmacological management of peripartum depression and comorbid anxiety in Europe. The recommendations need to be informed by the latest available evidence so that healthcare providers and women can make informed, evidence-based decisions about treatment choices.
Ultrastructural analysis of wild-type and RIM1α knockout active zones in a large cortical synapse
(2022)
Rab3A-interacting molecule (RIM) is crucial for fast Ca\(^{2+}\)-triggered synaptic vesicle (SV) release in presynaptic active zones (AZs). We investigated hippocampal giant mossy fiber bouton (MFB) AZ architecture in 3D using electron tomography of rapid cryo-immobilized acute brain slices in RIM1α\(^{−/−}\) and wild-type mice. In RIM1α\(^{−/−}\), AZs are larger with increased synaptic cleft widths and a 3-fold reduced number of tightly docked SVs (0–2 nm). The distance of tightly docked SVs to the AZ center is increased from 110 to 195 nm, and the width of their electron-dense material between outer SV membrane and AZ membrane is reduced. Furthermore, the SV pool in RIM1α\(^{−/−}\) is more heterogeneous. Thus, RIM1α, besides its role in tight SV docking, is crucial for synaptic architecture and vesicle pool organization in MFBs.
Background
Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorders for diagnostics, monitoring, and prognostication of disease course. It remains unclear if neuronal biomarkers may help detect cognitive impairment in this high-risk population. Also, the influence of chronic HF and concomitant renal dysfunction on these biomarkers is not well understood.
Methods
Within the monocentric Cognition.Matters-HF study, we quantified the serum levels of phosphorylated tau protein 181 (pTau) and neurofilament light chain (NfL) of 146 extensively phenotyped chronic heart failure patients (aged 32 to 85 years; 15.1% women) using ultrasensitive bead-based single-molecule immunoassays. The clinical work-up included advanced cognitive testing and cerebral magnetic resonance imaging (MRI).
Results
Serum concentrations of NfL ranged from 5.4 to 215.0 pg/ml (median 26.4 pg/ml) and of pTau from 0.51 to 9.22 pg/ml (median 1.57 pg/ml). We detected mild cognitive impairment (i.e., T-score < 40 in at least one cognitive domain) in 60% of heart failure patients. pTau (p = 0.014), but not NfL, was elevated in this group. Both NfL (ρ = − 0.21; p = 0.013) and pTau (ρ = − 0.25; p = 0.002) related to the cognitive domain visual/verbal memory, as well as white matter hyperintensity volume and cerebral and hippocampal atrophy. In multivariable analysis, both biomarkers were independently influenced by age (T = 4.6 for pTau; T = 5.9 for NfL) and glomerular filtration rate (T = − 2.4 for pTau; T = − 3.4 for NfL). Markers of chronic heart failure, left atrial volume index (T = 4.6) and NT-proBNP (T = 2.8), were further cardiological determinants of pTau and NfL, respectively. In addition, pTau was also strongly affected by serum creatine kinase levels (T = 6.5) and ferritin (T = − 3.1).
Conclusions
pTau and NfL serum levels are strongly influenced by age-dependent renal and cardiac dysfunction. These findings point towards the need for longitudinal examinations and consideration of frequent comorbidities when using neuronal serum biomarkers.
Background
Epigenetic mechanisms may play a major role in the biological embedding of early-life stress (ELS). One proposed mechanism is that glucocorticoid (GC) release following ELS exposure induces long-lasting alterations in DNA methylation (DNAm) of important regulatory genes of the stress response. Here, we investigate the dynamics of GC-dependent methylation changes in key regulatory regions of the FKBP5 locus in which ELS-associated DNAm changes have been reported.
Results
We repeatedly measured DNAm in human peripheral blood samples from 2 independent cohorts exposed to the GC agonist dexamethasone (DEX) using a targeted bisulfite sequencing approach, complemented by data from Illumina 450K arrays. We detected differentially methylated CpGs in enhancers co-localizing with GC receptor binding sites after acute DEX treatment (1 h, 3 h, 6 h), which returned to baseline levels within 23 h. These changes withstood correction for immune cell count differences. While we observed main effects of sex, age, body mass index, smoking, and depression symptoms on FKBP5 methylation levels, only the functional FKBP5 SNP (rs1360780) moderated the dynamic changes following DEX. This genotype effect was observed in both cohorts and included sites previously shown to be associated with ELS.
Conclusion
Our study highlights that DNAm levels within regulatory regions of the FKBP5 locus show dynamic changes following a GC challenge and suggest that factors influencing the dynamics of this regulation may contribute to the previously reported alterations in DNAm associated with current and past ELS exposure.
Aims
Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF.
Methods and results
Using bead-based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters-HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariable models, also accounting for multiple testing, were run. One hundred and forty-six chronic HF patients with a mean age of 63.8 ± 10.8 years were included (15.1% women). Serum GFAP levels (median 246 pg/mL, quartiles 165, 384 pg/mL; range 66 to 1512 pg/mL) did not differ between sexes. In the multivariable adjusted model, independent predictors of GFAP levels were age (T = 5.5; P < 0.001), smoking (T = 3.2; P = 0.002), estimated glomerular filtration rate (T = −4.7; P < 0.001), alanine aminotransferase (T = −2.1; P = 0.036), and the left atrial end-systolic volume index (T = 3.4; P = 0.004). NT-proBNP but not serum GFAP explained global cerebral atrophy beyond ageing. However, serum GFAP levels were associated with the cognitive domain visual/verbal memory (T = −3.0; P = 0.003) along with focal hippocampal atrophy (T = 2.3; P = 0.025).
Conclusions
Serum GFAP levels are affected by age, smoking, and surrogates of the severity of HF. The association of GFAP with memory dysfunction suggests that astroglial pathologies, which evade detection by conventional MRI, may contribute to memory loss beyond ageing in patients with chronic HF.
Introduction
Neurotransmitter release at presynaptic active zones (AZs) requires concerted protein interactions within a dense 3D nano-hemisphere. Among the complex protein meshwork the (M)unc-13 family member Unc-13 of Drosophila melanogaster is essential for docking of synaptic vesicles and transmitter release.
Methods
We employ minos-mediated integration cassette (MiMIC)-based gene editing using GFSTF (EGFP-FlAsH-StrepII-TEV-3xFlag) to endogenously tag all annotated Drosophila Unc-13 isoforms enabling visualization of endogenous Unc-13 expression within the central and peripheral nervous system.
Results and discussion
Electrophysiological characterization using two-electrode voltage clamp (TEVC) reveals that evoked and spontaneous synaptic transmission remain unaffected in unc-13\(^{GFSTF}\) 3rd instar larvae and acute presynaptic homeostatic potentiation (PHP) can be induced at control levels. Furthermore, multi-color structured-illumination shows precise co-localization of Unc-13\(^{GFSTF}\), Bruchpilot, and GluRIIA-receptor subunits within the synaptic mesoscale. Localization microscopy in combination with HDBSCAN algorithms detect Unc-13\(^{GFSTF}\) subclusters that move toward the AZ center during PHP with unaltered Unc-13\(^{GFSTF}\) protein levels.
Despite its negative reputation, egoism – the excessive concern for one’s own welfare – can incite prosocial behavior. So far, however, egoism-based prosociality has received little attention. Here, we first provide an overview of the conditions under which egoism turns into a prosocial motive, review the benefits and limitations of egoism-based prosociality, and compare them with empathy-driven prosocial behavior. Second, we summarize studies investigating the neural processing of egoism-based prosocial decisions, studies investigating the neural processing of empathy-based prosocial decisions, and the small number of studies that compared the neural processing of prosocial decisions elicited by the different motives. We conclude that there is evidence for differential neural networks involved in egoism and empathy-based prosocial decisions. However, this evidence is not yet conclusive, because it is mainly based on the comparison of different experimental paradigms which may exaggerate or overshadow the effect of the different motivational states. Finally, we propose paradigms and research questions that should be tackled in future research that could help to specify how egoism can be used to enhance other prosocial behavior and motivation, and the how it could be tamed.
To slow down the spread of the SARS-Cov-2 virus, countries worldwide severely restricted public and social life. In addition to the physical threat posed by the viral disease (COVID-19), the pandemic also has implications for psychological well-being. Using a small sample (N = 51), we examined how Big Five personality traits relate to coping with contact restrictions during three consecutive weeks in the first wave of the COVID-19 pandemic in Germany. We showed that extraversion was associated with suffering from severe contact restrictions and with benefiting from their relaxation. Individuals with high neuroticism did not show a change in their relatively poor coping with the restrictions over time, whereas conscientious individuals seemed to experience no discomfort and even positive feelings during the period of contact restrictions. Our results support the assumption that neuroticism is a vulnerability factor in relation to psychological wellbeing but also show an influence of contact restrictions on extraverted individuals.
Social anxiety disorder (SAD) is a highly prevalent and comorbid anxiety disorder with rather unclear underlying mechanisms. Here, we aimed to characterize neurobiological changes occurring in mice expressing symptoms of social fear and to identify possible therapeutic targets for SAD. Social fear was induced via social fear conditioning (SFC), a validated animal model of SAD. We assessed the expression levels of the immediate early genes (IEGs) cFos, Fosl2 and Arc as markers of neuronal activity and the expression levels of several genes of the GABAergic, serotoninergic, oxytocinergic, vasopressinergic and neuropeptide Y (NPY)-ergic systems in brain regions involved in social behavior or fear-related behavior in SFC+ and SFC− mice 2 h after exposure to a conspecific. SFC+ mice showed a decreased number and density of cFos-positive cells and decreased expression levels of IEGs in the dorsal hippocampus. SFC+ mice also showed alterations in the expression of NPY and serotonin system-related genes in the paraventricular nucleus of the hypothalamus, basolateral amygdala, septum and dorsal raphe nucleus, but not in the dorsal hippocampus. Our results describe neuronal alterations occurring during the expression of social fear and identify the NPY and serotonergic systems as possible targets in the treatment of SAD.
Due to the global aging society and the enormous global incidence and prevalence rates that will result in the coming years, Alzheimer's Dementia (AD) represents a growing challenge for the health care system. The pathogenesis, which is unclear in parts, the chronic progression of AD, which often lasts for years, as well as insufficient diagnostic and therapeutic options complicate an adequate psychotherapeutic and medical approach to the disease. To date, AD is also considered an incurable disease.
Therefore, it is essential to gain deeper insights into the early detection or even prevention of AD. Consideration of prodromal syndromes such as Mild Cognitive Impairment (MCI) can provide significant evidence about high-risk groups for AD progression and differentiate cognitively "normal" aging individuals from those with pathological cognitive decline. Thus, for example, functional Near-Infrared Spectroscopy (fNIRS) imaging helps identify early neurodegenerative processes. In contrast, potential risk factors and predictors of later-onset clinical symptoms of MCI and AD can most often be revealed and quantified via the use of neuropsychiatric test batteries.
The present thesis consists of four studies and aimed to assess and describe the pathological cognitive decline in a sample of elderly study participants (age: ≥ 70 years; N = 604 at baseline) of the longitudinal, observational, and prospective "Vogel Study" from Würzburg, Germany, who were primarily healthy at baseline, over two measurement time points approximately 3 years apart, to differentiate between healthy and diseased study participants and to define predictors of MCI/AD and longitudinal study dropout.
Studies 1 and 2 differentiated healthy study participants from MCI patients based on the baseline hemodynamic response of the parietal cortex recorded by fNIRS during the processing of a paradigm (here: Angle Discrimination Task [ADT]) for visual-spatial processing performance. Neuronal hypoactivity was found in the MCI patients, with both healthy study participants and MCI patients showing higher superior and right hemispheric activation. MCI patients had more difficulty resolving the paradigm. Thus, no evidence of possible compensatory mechanisms was uncovered in the MCI patients.
Study 3 first defined the four latent factors declarative memory, working memory, attention, and visual-spatial processing based on structural equation model (SEM) calculations of the sample using adequate measurement (in-)variant confirmatory factor models from the baseline assessment to the first of a total of two follow-up assessments after approximately 3 years. This allowed a dimensional assessment of pathological cognitive decline versus classificatory-categorical assignment (healthy/diseased) of the sample. In addition, the superiority of the latent factor approach over a composite approach was demonstrated. Next, using a mixed-model approach, predictive analyses were calculated for the prediction of latent factors at first follow-up by baseline risk factors. The sex of study participants proved to be the best predictor of cognitive change in all the cognitive domains, with females performing better than men in the memory domains. Specifically, for declarative memory, older age predicted lower performance regardless of sex. Additional predictive evidence emerged for low serum levels of Brain-Derived Neurotrophic Factor (BDNF) on lower attention performance and higher depression symptoms on lower visual-spatial processing performance.
Study 4 further reported baseline predictors of study dropout at first follow-up. Cognitive performance, as defined in Study 3 using the four latent cognitive factors, was a predictor of study dropout for cognitive decline in the domains of declarative memory, attention, and visual-spatial processing. Conspicuous dementia screening on the Mini-Mental Status Examination (MMSE) also predicted dropout.
Overall, both the use of fNIRS imaging to detect visual-spatial processing performance in the parietal cortex during applying ADT and the dimensional perspective of the neuropsychiatric test battery in the context of prediction and dropout analyses were found to be suitable for early detection research of MCI and AD. Finally, the results will be interpreted in the overall context and implications, limitations, and perspectives will be discussed.
Background
The efficacy of parent-child training (PCT) regarding child symptoms may be reduced if the mother has attention-deficit/hyperactivity disorder (ADHD). The AIMAC study (ADHD in Mothers and Children) aimed to compensate for the deteriorating effect of parental psychopathology by treating the mother (Step 1) before the beginning of PCT (Step 2). This secondary analysis was particularly concerned with the additional effect of the Step 2 PCT on child symptoms after the Step 1 treatment.
Methods
The analysis included 143 mothers and children (aged 6–12 years) both diagnosed with ADHD. The study design was a two-stage, two-arm parallel group trial (Step 1 treatment group [TG]: intensive treatment of the mother including psychotherapy and pharmacotherapy; Step 1 control group [CG]: supportive counseling only for mother; Step 2 TG and CG: PCT). Single- and multi-group analyses with piecewise linear latent growth curve models were applied to test for the effects of group and phase. Child symptoms (e.g., ADHD symptoms, disruptive behavior) were rated by three informants (blinded clinician, mother, teacher).
Results
Children in the TG showed a stronger improvement of their disruptive behavior as rated by mothers than those in the CG during Step 1 (Step 1: TG vs. CG). In the CG, according to reports of the blinded clinician and the mother, the reduction of children’s disruptive behavior was stronger during Step 2 than during Step 1 (CG: Step 1 vs. Step 2). In the TG, improvement of child outcome did not differ across treatment steps (TG: Step 1 vs. Step 2).
Conclusions
Intensive treatment of the mother including pharmacotherapy and psychotherapy may have small positive effects on the child’s disruptive behavior. PCT may be a valid treatment option for children with ADHD regarding disruptive behavior, even if mothers are not intensively treated beforehand.
Trial registration
ISRCTN registry ISRCTN73911400. Registered 29 March 2007.
Background
The onset of mental illness such as depression and anxiety disorders in pregnancy and postpartum period is common. The coronavirus induced disease 2019 (COVID-19) pandemic and the resulting public policy responses represent an exceptional situation worldwide and there are hints for adverse psychosocial impact, hence, the study of psychological effects of the pandemic in women during hospitalization for delivery and in the postpartum period is highly relevant.
Methods
Patients who gave birth during the first wave of the COVID-19 pandemic in Germany (March to June 2020) at the Department of Obstetrics and Gynecology, University of Würzburg, Germany, were recruited at hospital admission for delivery. Biosamples were collected for analysis of SARS-CoV-2 infection and various stress hormones and interleukin-6 (IL-6). In addition to sociodemographic and medical obstetric data, survey questionnaires in relation to concerns about and fear of COVID-19, depression, stress, anxiety, loneliness, maternal self-efficacy and the mother–child bonding were administered at T1 (delivery stay) and T2 (3–6 months postpartum).
Results
In total, all 94 recruited patients had a moderate concern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at T1 with a significant rise at T2. This concern correlated with low to low-medium general psychosocial stress levels and stress symptoms, and the women showed a significant increase of active coping from T1 to T2. Anxiety levels were low and the Edinburgh Postnatal Depression Scale showed a medium score of 5 with a significant (T1), but only week correlation with the concerns about SARS-CoV-2. In contrast to the overall good maternal bonding without correlation to SARS-CoV-2 concern, the maternal self-efficiency correlated negatively with the obstetric impairment caused by the COVID-19 pandemic.
Conclusion
Obstetric patients` concerns regarding SARS-CoV-2 and the accompanying pandemic increased during the course of the pandemic correlating positively with stress and depression. Of note is the increase in active coping over time and the overall good mother–child-bonding. Maternal self-efficacy was affected in part by the restrictions of the pandemic.
Empathy, the act of sharing another person’s affective state, is a ubiquitous driver for helping others and feeling close to them. These experiences are integral parts of human behavior and society. The studies presented in this dissertation aimed to investigate the sustainability and stability of social closeness and prosocial decision-making driven by empathy and other social motives. In this vein, four studies were conducted in which behavioral and neural indicators of empathy sustainability were identified using model-based functional magnetic resonance imaging (fMRI).
Applying reinforcement learning, drift-diffusion modelling (DDM), and fMRI, the first two studies were designed to investigate the formation and sustainability of empathy-related social closeness (study 1) and examined how sustainably empathy led to prosocial behavior (study 2). Using DDM and fMRI, the last two studies investigated how empathy combined with reciprocity, the social norm to return a favor, on the one hand and empathy combined with the motive of outcome maximization on the other hand altered the behavioral and neural social decision process.
The results showed that empathy-related social closeness and prosocial decision tendencies persisted even if empathy was rarely reinforced. The sustainability of these empathy effects was related to recalibration of the empathy-related social closeness learning signal (study 1) and the maintenance of a prosocial decision bias (study 2). The findings of study 3 showed that empathy boosted the processing of reciprocity-based social decisions, but not vice versa. Study 4 revealed that empathy-related decisions were modulated by the motive of outcome maximization, depending on individual differences in state empathy.
Together, the studies strongly support the concept of empathy as a sustainable driver of social closeness and prosocial behavior.
Background
In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process.
Study design
This multi-center, prospective controlled study has a two-phase cohort design.
Methods
Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2).
Outcomes
Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach.
Conclusions
This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease.
Spin-lock based functional magnetic resonance imaging (fMRI) has the potential for direct spatially-resolved detection of neuronal activity and thus may represent an important step for basic research in neuroscience. In this work, the corresponding fundamental effect of Rotary EXcitation (REX) is investigated both in simulations as well as in phantom and in vivo experiments. An empirical law for predicting optimal spin-lock pulse durations for maximum magnetic field sensitivity was found. Experimental conditions were established that allow robust detection of ultra-weak magnetic field oscillations with simultaneous compensation of static field inhomogeneities. Furthermore, this work presents a novel concept for the emulation of brain activity utilizing the built-in MRI gradient system, which allows REX sequences to be validated in vivo under controlled and reproducible conditions. Via transmission of Rotary EXcitation (tREX), we successfully detected magnetic field oscillations in the lower nano-Tesla range in brain tissue. Moreover, tREX paves the way for the quantification of biomagnetic fields.
Fear and anxiety disorders – interaction of AVP and OXT brain systems with the serotonergic system
(2023)
Anxiety disorders pose a great burden onto society and economy and can have devastating consequences for affected individuals. Treatment options are still limited to psychopharmacotherapy originally developed for the treatment of depression and behavioral therapy. A combination of genetic traits together with aversive events is most likely the cause of these diseases. Gene x environment studies are trying to find a link between genetic traits and specific negative circumstances. In a first study, we focused on social anxiety disorder (SAD), which is the second most-common anxiety disorder after specific phobias. We used a social fear conditioning (SFC) paradigm, which is able to mimic the disease in a mouse model. We wanted to investigate protein levels, as well as mRNA expression of immediate early genes (IEGs), to determine brain areas affected by the paradigm. We also included genes of the vasopressin (AVP)-, oxytocin (OXT)-, neuropeptide Y (NPY)-, and the serotonin system, to investigate the effects of SFC on neurotransmitter gene expression levels in brain regions related to social as well as fear-related behavior. AVP and OXT regulate a lot of different social and anxiety-related behaviors, both positive and negative. Finding a link between different neurotransmitter systems in the development of anxiety disorders could help to identify potential targets for new treatment approaches, which are desperately needed, because the rate of patients not responding to available treatment is very high.
We were able to show altered gene expression of the IEGs cFos and Fosl2, as well as a change in number and density of cFOS-positive cells in the dorsal hippocampus, indicating an influence of SFC on neuronal activity. Our results reveal a possible involvement of anterior dentate gyrus (DG), as well as cornu ammonis area 1 (CA1) and CA3 in the dorsal hippocampus during the expression of social fear. Contrary to our hypothesis, we were not able to see changes in neuronal activity through expression changes of IEGs in the amygdala. Significant higher IEG immunoreactivity and gene expression in the dorsal hippocampus of animals without fear conditioning (SFC-), compared to animals with fear conditioning (SFC+), indicate an involvement of different hippocampal regions in two possible scenarios. Either as elevated gene expression in SFC- animals compared to SFC+ animals or as reduction in SFC+ animals compared to SFC- animals. However, this question cannot be answered without an additional control of basal IEG-activity without social interaction. The NPY system in general and the neuropeptide y receptor type 2 in particular seem to be involved in regulating the response to social fear, mostly through the septum region. In addition to that, a possible role for the induction of social fear response could be identified in the serotonergic system and especially the serotonin receptor 2a of the PVN.
In a second study we focused on changes in the serotonergic system. A polymorphism in the human serotonin transporter (5-HTT) gene is associated with higher risks for the development of anxiety disorders. This makes the 5-HTT a widely used target to study possible causes and the development of anxiety disorders. In mice, a genetically induced knockout of the 5-Htt gene is associated with increased anxiety-like behavior. High amounts of stress during pregnancy, also known as prenatal stress, significantly increase the risk to develop psychiatric disorders for the unborn child. We utilized a prenatal stress paradigm in mice heterozygous for the 5-Htt gene. Some of the animals which had been subjected to prenatal stress showed noticeably “unsocial” interaction behavior towards conspecifics. Again, we were searching for links between the serotonergic system and AVP- and OXT systems. Through quantitative gene expression analysis, we were able to show that both AVP and OXT neuromodulator systems are affected through prenatal stress in female mice, but not in male mice. The 5-Htt genotype seems to be only slightly influential to AVP, OXT or any other neurotransmitter system investigated. Gene expression of AVP and OXT brain systems is highly influenced through the estrous cycle stages of female mice. Additionally, we analyzed the AVP and OXT neuropeptide levels of mice with different 5-Htt genotypes and in both sexes, in order to see whether the production of AVP and OXT is influenced by 5-Htt genotype. On neuropeptide level, we were able to identify a sex difference for vasopressin-immunoreactive (ir) cells in the PVN, with male mice harboring significantly more positive cells than female mice.